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1
Abstract
Neurodegenerative diseases (NDs), such as Alzheimer’s disease and Parkinson’s dis-
ease, are devastating disorders that progress to severe disability and death. Currently,
there is no cure for these diseases.
The common hallmark of NDs is the progressive deposition of misfolded protein
aggregates, rich in amyloid-like β-sheet structures. Moreover, the etiology of these
diseases at the molecular level is extremely complex and malfunction of diverse cellular
pathways, including protein degradation mechanisms, mitochondrial homeostasis,
neurotrophic signaling, and nucleocytoplasmic transport have been shown to be
involved. Despite great advances in last decades in the comprehension of how these
diseases develop, the precise mechanisms leading to neurodegeneration are still not
fully understood. One difficulty in deciphering these mechanisms is the co-existence of
loss of function effects, due to the impaired structure of the aggregating protein, and
gain of function effects, due to the cytotoxic properties of the misfolded conformation.
In this thesis, I have used rationally designed proteins which form amyloid-like β-
sheet structures as a tool to investigate the toxicity mechanisms of protein aggregation
in the absence of potential loss of function effects. First, we confirmed that β-sheet
proteins form aggregates in primary cultured neurons. Moreover, expression of these
proteins resulted in impaired neuronal morphology and progressive neuronal death.
Reduced Akt phosphorylation suggested that impaired neurotrophic signaling might
be involved in the cause of neuronal death.
To further investigate the molecular signature of β-sheet-induced toxicity, we
performed interactome mass spectrometry analysis in primary neurons. This approach
revealed that a variety of proteins, some of them essential for neuronal survival, form
aberrant interactions with the β-sheet proteins. Therefore, the list of interacting
proteins constitutes a resource of candidates which might be potentially involved in
common mechanisms of aggregation toxicity.
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In addition, we generated a novel inducible transgenic mouse line to study amyloid-
like aggregation effects in vivo. β-sheet protein expression in the forebrain resulted in
aggregate formation, brain atrophy and interfered with nucleocytoplasmic transport
components, while no effects on mouse behavior were detected. Moreover, β-sheet
protein expression in the whole central nervous system during embryogenesis was
lethal, suggesting a strong cellular toxicity phenotype. Hence, the observed lethality
requires further investigation.
Overall, we adopted an integrative and multidisciplinary approach that confirmed
the use of artificial aggregating proteins as an asset to decipher gain of function effects
of protein aggregation. Further studies using the β-sheet proteins to unravel common
underlying mechanisms of aggregation toxicity in NDs may enable the therapeutic
targeting of a whole range of disorders.
2
Introduction
2.1 Protein aggregation in neurodegenerative diseases
Life expectancy has risen worldwide at fast pace during the last century. Since
aging is a common risk factor for Neurodegenerative diseases (NDs), their prevalence is
also rising. As an example, in 2015 around 47 million people were living with dementia
worldwide, and this number is expected to increase to approximately 131 million
people by 2050. This does not only affect people who suffer from these illnesses, but
also relatives, friends, and eventually, the whole society [1, 2]. In spite of great efforts
in research, industry, and clinics, there is currently no cure for neurodegenerative dis-
eases. However, our knowledge about these diseases has vastly improved in last decades.
The group of neurodegenerative diseases includes some of the most debilitating
disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s
disease (HD), Amyotrophic lateral sclerosis (ALS), Spinocerebellar ataxia (SCA),
Frontotemporal dementia (FTD), dementia with Lewy bodies, and Prion diseases
(PrD), among others. These diseases present diverse clinical symptoms, affecting
cognition and movements. In AD, which is the most prevalent ND, patients suffer from
progressive memory loss and dementia. In contrast, PD characteristic symptoms are
resting tremor, rigidity, bradikynesia, and occasionally dementia [3, 4]. HD has a broad
impact on a person’s functional abilities, resulting in movement problems (including
involuntary movements and impairments in voluntary movements), cognitive problems,
and psychiatric problems as depression [5]. People affected by ALS, which is a type of
motor neuron disease, experience lack of control in muscles needed to move, eat, and
breathe. Interestingly, ALS and FTD show clinical overlap, as dementia symptoms
can be seen in ALS patients and neuromuscular signs can be seen in FTD patients [6].
Despite the variety in clinical manifestations, NDs share some common features:
most of them have both sporadic and inherited origin (except for HD and SCA, which
are inherited in an autosomal dominant manner), they appear late in life, and patients
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present brain mass loss with characteristic neuronal loss and synaptic abnormalities,
which are in turn reflected in specific clinical symptoms. Moreover, the common
hallmark of NDs is the progressive deposition of intra- and/or extracellular protein
aggregates. This commonality of protein misfolding and aggregate accumulation ac-
cros diseases has prompted researchers to refer to NDs as protein misfolding diseases [7].
The aggregating proteins in each disease have different sequence, structure, expres-
sion levels, and function. Nevertherless, they all misfold and self-assemble forming
well-ordered β-sheet-rich structures (except for SOD1, TDP-43, and FUS in ALS;
their structure is under discussion), ranging from small oligomers to large fibrillar
aggregates, the latter usually referred to as amyloid. Structural analysis has shown
that amyloid consists of ordered arrays of β-sheets running parallel to the long axis
of the fibrils, a structure known as cross-β [8]. Moreover, amyloid fibrils are thread-
like structures typically 7–13 nm in diameter, as observed by electron microscopy
(EM), and often microns in length. Finally, amyloid structures are characteristically
identified by the binding of dyes, such as thioflavin-T, Congo red, or their derivatives [9].
The amyloid polymerization mechanism can be best described by the seeding-
nucleation model [10, 11], shown in schematics in Figure 2.1. This model proposes
that the formation of a stable protein nucleus that acts as a seed to further propagate
protein misfolding is the critical event. The process of seed formation is slow,
thermodynamically unfavorable, and followed by a rapid elongation with incorporation
of soluble monomeric protein into the aggregate. Likely, conformational changes
to form the β-strands facilitate aggregation. In particular, hydrophobic groups
usually buried inside the protein structure become exposed to the solvent and this
makes proteins prone to intermolecular interactions [9]. Interestingly, evolutionary
selection might have reduced segments of alternating hydrophilic and hydrophobic
residues that favor β-sheet formation. Analysis of a large database of protein
sequences derived from many different organisms revealed that alternating patterns oc-
cur less frequently than other patterns with the same polar/non-polar composition [12].
Remarkably, secondary processes, such as fragmentation events and secondary
nucleation reactions, can as well be important in aggregation kinetics. Fragmentation
events refer to a growing fibrillar aggregate breaking into smaller pieces, which can free
oligomeric species. In secondary nucleation reactions the surfaces of growing fibrils
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catalyze the formation of new clusters of monomers that act as nuclei, increasing the
number of growth-competent aggregate species and hence accelerating the overall
aggregation rate. Finally, it is also important to note, that variations on the common
cross-β-sheet conformation might be present at detailed structural level due to
differences in aminoacid sequence, chain lengths, as well as solution conditions [9].
Figure 2.1: Mechanism of amyloid fibril formation. Monomeric proteins can misfold
and aggregate in a thermodynamically unfavorable process to form a protein seed or nuclei
(red arrows). Such seeds can be considered as the smallest structures that are able to initiate
fibril elongation. During the misfolding process, the folding or degradation machineries of
the cell can intervene to properly fold or degrade the misfolded protein species (blue arrows).
Otherwise, fibrils grow rapidly through the addition of monomers to these seeds. Finally,
secondary processes, such as fragmentation or secondary nucleation can occur, leading to
further misfolding. Adapted from [7, 9, 13].
2.1.1 Key aggregating proteins and genetics in neurodegeneration
Within the different diseases, specific proteins form aggregates in particular
locations. Extracellular deposits of amyloid-β protein (Aβ), so called amyloid plaques,
and cytoplasmic neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein
are characteristic in AD. Cases of familial AD account for 1–5% of patients and
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lead to inherited, early onset AD [3]. These cases are the result of autosomal,
dominant mutations in three genes: the amyloid-β precursor protein gene (APP) [14],
presenilin-1 (PSEN1 ), or presenilin-2 (PSEN2 ) [15, 16]. PSEN1 and PSEN2 encode
for active subunits of the gamma secretase complex, an amyloid-β processing-pathway
component [17, 18, 19]. Moreover, duplications of the APP locus also cause familial
AD [20]. These first discoveries and the consequent advances in understanding the
disease genetics, favored the postulation of the amyloid cascade hypothesis, which
places the changes in Aβ metabolism as triggers of AD pathophysiology, leading to
neurofibrillary tangles and neurodegeneration that cause memory loss [21]. Moreover,
other heritable genetic risk factors contribute to an individual’s susceptibility to
late-onset AD, be it because they increase Aβ accumulation, as for apolipoprotein E
(APOE) mutations [22, 23], or because they result in impaired Aβ clearance, as for
mutations in TREM2 (a transmembrane receptor highly expressed in microglia and
myeloid cells) [24]. Mutations in the MAPT gene, encoding for protein tau, usually
result in FTD, a tauopathy causing dementia [25].
Intraneural aggregates of α-synuclein, termed Lewy bodies and Lewy neurites [26],
are typical in neurons of the substantia nigra in PD patients. PD is the most common
neurodegenerative movement disorder and its motor symptoms result from selective loss
of dopaminergic neurons in the pars compacta of the substancia nigra in the midbrain,
together with the loss of their axon terminals, which project to the dorsal striatum
[4]. Approximately 5-10% of PD cases are caused by familial genetic mutations and
the first gene to be linked to familial PD was SNCA, coding for α-synuclein protein
(α-syn) [27]. Missense, as well as multiplication mutations (duplication or triplication
of the loci) in SNCA result in genetic dominant forms of PD [28, 29]. Alternatively, the
most prevalent genetic cause of familial PD are mutations in LRRK2, which lead to
diverse pathologies including Lewy bodies and nigral degeneration [30, 31]. Moreover,
autosomal recessive mutations in the lysosomal hydrolase glucocerebrosidase (GBA)
lead to Gaucher’s disease, which is characterized by neurological features that include
parkinsonism. A feedback loop between α-synuclein and GBA has been suggested,
since GBA loss in iPS neurons causes accumulation of α-synuclein [32]. Mutations in
other genes including Parkin [33, 34], PTEN-induced putative kinase 1 PINK1 [35],
and DJ-1 [36] are as well causes of autosomal recessive PD.
HD is a monogenic, fully penetrant disease, caused by a CAG trinucleotide repeat
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expansion within exon 1 of the HTT gene on chromosome 4. People with more than 39
CAG repeats are certain to develop the disease, whereas 36 to 39 repeats are associated
with reduced penetrance. A range between 27-35 repeats is considered intermediate
because it may increase the likelihood of repeat instability, while below 27 is normal.
CAG expansions result in an elongated polyglutamine (polyQ) tract at the N-terminal
of the huntingtin protein (HTT) which leads to protein aggregation. Longer CAG
repeats predict earlier onset, accounting for approximately 56% of the variability in
age onset [37]. At the cellular level, patients suffer from massive striatal neuronal
death, with up to 95% loss of GABAergic medium spiny neurons (MSNs), whereas
large interneurons are selectively spared [38]. Furthermore, atrophy is also detected in
the cortex, thalamus, sub-thalamic nucleus, white matter, and cerebellum, although
less severe than in the striatum [39, 5]. In spite of the early discovery of the HTT
gene [40], understanding of HD mechanisms is still evolving, due to its tremendously
complex pathogenesis.
In ALS, motor neurons accumulate inclusions of aggregated proteins that vary
depending on the ALS subtype. This disease is invariably fatal, with death typically
occurring 3 to 5 years after diagnosis, and about 10% of cases are transmitted within
families. Autopsies of people with ALS reveal the degeneration of motor neurons in
the motor cortex of the brain, in the brainstem motor nuclei and in the anterior horns
of the spinal cord [6]. In familial cases, protein aggregates are often composed of
mutated superoxide dismutase 1 (SOD1), and mutations in the SOD1 gene cause ALS
[41]. Misfolded SOD1 forms ubiquitinated cytoplasmic inclusions that progressively
accumulate as disease progresses [42]. Moreover, inclusions of mutated TDP-43 [43],
FUS [44], or Optineurin [45] can be detected in approximately 5% of familial cases.
Notably, TDP-43 and FUS are usually harbored in the nucleus, whilst in ALS they
are accumulated in the cytoplasm [46, 44].
In 2011, the most common genetic cause of ALS and FTD was identified, a
pathogenic hexanucleotide repeat in the non-coding region of the C9orf72 (C9) gene.
The sequence GGGGCC (G4C2) was detected to be expanded to hundreds or thou-
sands of repeats in affected individuals, while 2 to 23 repeats are present in healthy
ones [47, 48]. Apart from a reduction in the expression levels of the C9orf72 gene and
the accumulation of RNA foci containing the G4C2 repeats in the brains and spinal
cord of people with C9 ALS-FTD, also dipeptide-repeat proteins (DPRs) accumulate
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in neuronal cytoplasmic and intranuclear inclusions. DPR inclusions contain p62 and
are distinct from TDP-43 inclusions, which are also present in these individuals [49].
DPR toxicity mechanisms have gained a lot of attention in recent years, particularly
because DPRs are produced by repeat-associated non-AUG (RAN) translation [50, 51].
RAN is an unconventional type of translation firstly described in SCA8 [52], which
occurs in absence of an AUG initiation codon. RAN translation in C9 ALS-FTD
occurs in all reading frames and from both sense and antisense transcripts, resulting in
five DRP proteins (GA, GR, PR, PA, and GP). Strikingly, sense and antisense RAN
proteins derived from the CAG expansion in HTT have been reported to accumulate
in Huntington brains [53].
2.1.2 Cytotoxicity in neurodegeneration: loss or gain of function?
The link between pathogenic mutations and aggregation provides strong genetic
evidence that protein aggregation is a primary event in disease pathogenesis, rather
than a secondary event. Nevertheless, the relationship between protein aggregation
and cell death is currently not fully understood. Classically, three non-exclussive
hypotheses have been proposed to give an explanation for how misfolding and aggre-
gation associate with neuronal apoptosis [54]. Intuitively, one of them is the loss of
normal activity of the aggregating protein, referred to as loss of function hypothesis.
This hypothesis is backed-up by the fact that HTT knock-out (KO) mice are not viable
and die early in development [55, 56]. However, heterozygous mice reach adulthood
with a normal phenotype. As for proteins related to other diseases, SOD1 deficient
mice develop normally and show no motor symptoms [57]. APP and α-synuclein KO
mice are viable and show no signs of neurodegeneration, although α-synuclein loss
results in functional deficits in the nigrostriatal dopamine system [58, 59]. Finally, a
recent study has reported that conditional C9orf72 loss does not cause motor neuron
degeneration or motor deficits [60]. Nonetheless, another study showed that loss of
C9orf72 in mice leads to lysosomal accumulation and altered immune responses [61].
Overall, although loss of function of the aggregating protein might contribute to
disease, evidence suggests that it is not the sole cause of neurodegeneration.
Alternatively, the brain inflammation hypothesis poses chronic inflammatory
reactions triggered by protein aggregation as the leading cause of neuronal death and
synaptic changes. Evidence for chronic inflammation reactions in patients include:
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extensive astrogliosis and microgliosis, especially around protein aggregates, and
accumulation of inflammatory proteins such as cytokines and chemokines [62]. Glia
not only become reactive in response to degenerative cues, but can also participate in
trying to combat them. For example, both microglia and astrocytes are thought to
contribute to clearing Aβ [63, 64].
Maladaptive immune responses were initially thought to be caused by neurodegen-
eration. However, recent investigations suggest that inflammation might be involved as
a driving force in neurodegenerative disease pathogenesis [65]. For example, astrogliosis
has been detected in prodromal AD [66]. Moreover, in a coculture model composed of
human adult primary sporadic ALS astrocytes and human embryonic stem-cell-derived
motor neurons, ALS astrocytes, but not control astrocytes, triggered selective motor
neuron death by necroptosis [67]. Whole-genome sequencing studies revealed that rare
mutations in the microglia-enriched gene triggering receptor expressed on myeloid cells
2 (TREM2) significantly increased the risk of late onset AD [68, 69]. In a bioinformatics
study, module group innate immunity/microglia related genes correlated best with
clinical disease in sporadic AD [70]. In addition, progranulin, which is highly expressed
in microglia, is a major cause of familial FTD in haploinsufficient patients [71]. As
a final example, it was recently described that maladaptive microglia might damage
neuronal circuits through synaptic pruning or cytokine signaling [72]. In summary, the
involvement of glia in NDs is a matter of current intensive research and discussion, and
defining the molecular basis of protective and detrimental aspects of glial reactivity
may help to identify novel therapeutic strategies.
The third and most accepted hypothesis is the gain of function, by which misfolded
proteins acquire neurotoxic functions. As mentioned above, plenty of genetic evidence
suggest that protein misfolding, oligomerization, and aggregation are causative to
disease pathogenesis, and this may be entirely unrelated to the normal function of the
affected protein. Eearly in vitro studies recapitulated neuronal apoptosis induction
by protein aggregates: murine cortical cultures went into apoptosis when treated
with Aβ-42 [73], overexpression of mutant HTT in a neuroblastoma cell line resulted
in enhanced apoptosis [74], and SH-SY5Y cells entered apoptotic cell death upon
α-synuclein aggregate formation [75].
Additional support for this hypothesis has been provided by experiments in
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transgenic animals in which incorporation of the human mutated gene encoding the
misfolded protein can trigger neurodegeneration. For instance, the widely studied
R6/2 mouse model expresses the mutated exon 1 of the human HTT gene, with
over 100 CAG repeats, which leads to a fast progressing HD-like phenotype [76].
Mutated human tau expression in mice results in age-related NFTs, neuronal loss, and
behavioral impairments [77]. Several AD mouse models, such as the APP/PS1 [78]
and the 5xFAD [79], have been generated to express mutated forms of human APP,
PS1 and PS2, leading to amyloid plaque formation, as well as to behavioral traits
presented by AD patients. Importantly, not only mice, but also other animals such as
the fruit fly Drosophila melanogaster, rats, and non-human primates have been used
to show that protein misfolding and aggregation result in neuronal death [80]. Finally,
aggregation of non-disease related proteins can also result in cytotoxicity in cell lines
[81, 82], highlighting the possibility of common disease mechanisms among different
diseases.
2.1.3 Toxic protein species
Not only the how in protein aggregation is a matter of research, but also the
what. Nowadays, it has not yet been established, if either large insoluble aggregates,
or smaller oligomeric species represent the main neurotoxic agents. Although it was
initially thought that large protein deposits were the neurotoxic species in the brain,
studies indicate that prefibrillar aggregates or soluble oligomers might be the most
toxic species [83].
Aβ oligomers extracted from the cerebral cortex of AD patients caused memory
deficits and disrupted synaptic plasticity in rats. In contrast, insoluble amyloid plaque
cores from AD cortex did not impair long-term potentiation (LTP) unless they were
first solubilized to release Aβ dimers [84]. In an AD transgenic mouse model which
presented no extracellular plaques, Aβ oligomers accumulated in the neurons, leading
to memory and synaptic dysfunction, and tau hyperphosphorilation [85]. Further-
more, by lentivirus injections into the rat brain, it was observed that most severe
dopaminergic loss in the substantia nigra occured in animals with the α-syn variants
that formed oligomers, whereas the rapidly forming fibrils variants of α-syn were less
toxic [86]. Finally, biochemically-measured levels of soluble Aβ, including soluble
oligomers, correlate better with the presence and degree of cognitive deficits in AD
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than do plaque counts [87]. This evidence suggests that soluble forms might be better
candidates for inducing neuronal and synaptic dysfunction than fibrillar aggregates.
Indeed, it is this association with pathogenesis that favored research aiming at isolating
and determining the structure of oligomeres, as well as their structural determinants
of toxicity. However, the structural heterogeneity and transient nature of any given
oligomer population, combined with the frequently multiple parallel pathways to
oligomeric species formation, greatly complicate the task [9].
Two major structural determinants have been shown to explain the differential
toxicity of amyloid oligomers and fibrils. The first is the exposure of hydrophobic
groups on the oligomeric surface. In fact, oligomeric species of similar sizes and
morphologies, but having very different toxicities, have been isolated and shown to
differ in their solvent-exposed hydrophobicity [88, 89]. The second determinant is the
size, oligomers are smaller than fibrils and can therefore diffuse better in membranes
and tissues [90, 91]. Moreover, oligomers can also aberrantly interact with different
molecular targets, leading to a variety of toxicity mechanisms. Therefore, it has been
proposed that formation of big fibrillar aggregates could be a protective mechanism
designed to reduce the pool of sites for aberrant interactions, as shown for HTT in a
cell culture study of HD [92].
However, it is important to note that amyloid fibrils are far from innocuous
material. They can as well form aberrant interactions with cellular components
and deplete key members of the protein homeostasis network [13]. Perhaps most
importantly, fibrils can act as a reservoir of protein oligomers that can be released,
and act as potent catalysts for the generation of toxic oligomers through secondary
nucleation [93]. Hence it is unlikely that there is a sole neurotoxic agent causing
neurodegenerative diseases, but rather a variety of toxic misfolded protein species.
The importance of characterizing the different structural conformations of mis-
folded proteins lies not only in the cytotoxicity they can directly exert, but also
in their propagation capacity. In recent years, it has been gradually accepted that
misfolded protein aggregates can spread pathologically by a prion-like mechanism
in various cellular and animal models of diverse diseases. Studies with Aβ [94], tau
[95, 96], α-syn [97], SOD1 [98], and HTT [99, 100] have shown that inoculation with
tissue homogenates rich in misfolded proteins from patients or transgenic mouse
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models of NDs results in disease pathology induction in the recipient cells or animals.
Furthermore, transmission of α-syn and tau disease pathology has been observed in
inoculated nontransgenic mice [101, 102].
Remarkably, several studies have reported the existence of conformational variants,
referred as conformational strains, for misfolded protein aggregates composed of Aβ
[103], tau [104, 105], and α-syn [106, 107]. These findings may provide an explanation
for the heterogeneity observed in AD and PD patients. Altogether, these studies indi-
cate that promoting protein misfolding not only leads to increased protein aggregation,
but might accelerate disease progression. In that regard, it however remains an open
issue whether spreading of protein misfolding is equivalent to disease spreading [7].
Pathology-mapping studies in postmortem brain tissue suggest that disease proteins
accumulate in regions of primary vulnerability and spread to regions of secondary
vulnerability along anatomical connections [108, 109]. However, why specific proteins
initially accumulate in one and not another set of cells, presenting selective neuronal
vulnerability, remains an open question [110].
2.2 Molecular mechanisms of toxicity in neurodegeneration
The molecular underpinnings of neurodegenerative diseases are subject of ex-
tensive research and a number of studies have revealed the multifactorial etiology
of neurodegeneration [111]. Interestingly, alterations of common neuronal path-
ways such as protein quality control and degradation mechanisms, mitochondrial
homeostasis, and synaptic toxicity have been described. Mechanisms that will be
highlighted here because they have been especially investigated during the develop-
ment of this thesis include: aberrant protein interactions with misfolded aggregating
proteins, nucleocytoplasmic transport (NCT) impairments, and defects in trophic
signaling. Other research areas in neurodegeneration, such as non-cell-autonomous
mechanisms and dysfunctional neuronal connectivity, will not be referred to as in detail.
2.2.1 Aberrant protein interactions: interactome studies
As mentioned above, protein misfolding and aggregation result in exposure of
hydrophobic residues, rendering the misfolded protein prone to aberrant interactions.
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To try to pin down which molecules and pathways are affected by these aberrant
interactions, probably contributing to pathogenesis, interactome studies have been
performed. Broadly, these studies can be divided according to their approach: focusing
either on a single aggregating protein and identifying its interaction partners, or
analyzing several aggregating proteins and their common and specific interactors.
Within the first group, HTT has been mostly studied. In a combination of yeast
two-hybrid screening with affinity pull down followed by Mass Spectrometry (MS),
several genetic modifiers of neurodegeneration were identified and validated in a
Drosophila HD model. Interacting proteins confirmed as modifiers of the neurode-
generation phenotype represented a diverse array of biological functions, including
synaptic transmission, cytoskeletal organization, and signal transduction [112]. An
in vivo study using lysates from different brain regions of BACHD mice (a bacterial
artificial chromosome (BAC)-mediated transgenic mouse model expressing full-length
human mutant huntingtin with 97Q repeats [113]), reported a spatiotemporal analysis
of HTT interacting proteins via affinity-purification mass spectrometry (AP-MS). The
authors of this study identified that proteins involved in protein kinase A signalling
and mitochondrial dysfunction are enriched in the HTT interactome [114]. Moreover,
a recent study dissected the interactomes of oligomers and insoluble inclusions
of mutant HTT in neuroblastoma cells. Interestingly, oligomers interacted with
nuclear proteins and proteins associated with RNA and DNA binding/translation,
intracellular transport and ribosome biogenesis, whereas the interactome of insolu-
ble HTT was significantly enriched in chaperones and proteolysis-related proteins [115].
With regard to other aggregating proteins, the interactome of mutant tau P301L
was analyzed by tandem mass spectrometry in neuroblastoma N2A cells, reporting an
association of tau with the ribonucleoproteome [116]. Recently, another group iden-
tified the tau interactor Otub1, which functions as a tau deubiquitinating enzyme in
vitro and in vivo, and impairs tau degradation [117]. In terms of ALS-related proteins,
quantitative mass spectrometry analysis to identify DPR poly-GA co-aggregating
proteins revealed a significant enrichment of proteins of the Ubiquitin-proteasome
system (UPS) and identified the transport factor Unc119 as a modifier of toxicity
in neurons [118]. Finally, another study characterizing the neuronal interactomes of
DPRs poly-GR and poly-PR, detected components of stress granules, nucleoli, and
ribosomes. Furthermore, it highlighted the partial sequestration of ribosomes as a
24 2. Introduction
pathogenic mechanism, by potential chronic impairment of protein synthesis [119].
Two other reports aimed at unraveling and comparing the interactomes of mul-
tiple proteins related to neurodegenerative diseases. In the first study, the authors
performed analysis to identify binding partners of wild-type (wt) and ALS-associated
mutant versions of Ataxin-2 (ATXN2), C9orf72, Fus, Optineurin (OPTN), TDP-43
and Ubiquilin-2 (UBQLN2) in N2A cells [120]. Surprisingly, interactomes of WT and
mutant ALS proteins were very similar, except for OPTN and UBQLN2. Shared
binding partners of ATXN2, FUS and TDP-43 had roles in RNA metabolism; OPTN-
and UBQLN2-interacting proteins were related to protein degradation and protein
transport, and C9orf72 interactors had mitochondria-associated functions [120]. In the
second study, the interactomes of APP, PSEN1, PD related Parkin (PARK2), HTT,
and ATXN1 were described [121]. In this case, these proteins were overexpressed
in HEK293T cells and lysates measured by quantitative AP-MS. Strikingly, some
shared interaction partners were detected, although most protein-protein interactions
were unique for a single disease [121]. In conclusion, interactomic analysis repre-
sent a powerful tool to unravel dysfunctional cellular mechanisms in neurodegeneration.
Furthermore, total proteome studies have been very useful in neurodegeneration
research. For example, analysis of the insoluble fraction of human brain proteomes of
non-demented individuals, Mild cognitive impairment (MCI) cases, and symptomatic
AD cases, showed an upregulation of U1 small nuclear ribonucleoproteins [122]. This
result was confirmed by an independent study [123]. Moreover, an elegant research
combined transcriptomic and proteomic analysis in several mouse models of HD at
different ages. This study linked mutant HTT CAG repeat length and age to the degree
of impairment in the expression of identity genes for striatal medium spiny neurons, the
dysregulation of cyclic AMP signaling, and to cell death [124]. A complementary and
labor-intensive report, characterized the soluble and insoluble proteome of the R6/2
mouse model of HD at several ages and brain regions, identifying particular loss of
function protein candidates with potential therapeutic interest [125]. Finally, another
group reported the association between changes in solubility of hundreds of proteins
in the central nervous system (CNS), with pathological accumulations of misfolded
tau, α-synuclein and mutant SOD1 in CNS of transgenic mice. Remarkably, a subset
of the proteins that display a shift towards insolubility were common between these
different models, suggesting that a specific subset of the proteome is vulnerable to
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proteostatic disruption [126]. In summary, besides interactomic studies, analysis of the
total proteome has proven crucial to gain insight into protein misfolding pathogenesis.
2.2.2 Nucleocytoplasmic transport impairment
A notable commonality among several aggregated proteins is that they alter
nucleocytoplasmic transport, which can have toxic consequences. NCT refers to the
import of molecules from the cytoplasm to the nucleus and export from the nucleus
to the cytoplasm. NCT is regulated by nuclear pore complexes (NPC), large protein
complexes embedded in the nuclear membrane which allow communication between
the nucleoplasm and the cytoplasm. Each NPC is composed of multiple copies of 30
different and evolutionary conserved proteins termed nucleoporins (Nups). Interest-
ingly, the central channel of nuclear pores is formed by Nups containing low complexity
phenylalanine–glycine (FG) domains that are thought to form hydrogel-like structures
to create a selective permeable sieve. Indeed, small molecules can passively diffuse
through the NPC, while molecules exceeding around 40 nm are actively transported,
requiring energy. Active protein transport through the NPC is regulated via nuclear
transport receptors, known as importins and exportins [127].
Moreover, active transport is dependent on Ran, a nuclear GTP-binding protein,
which regulates the ability of importins and exportins to transport their cargo across
the nuclear membrane depending on the bound nucleotide state. That is, during export,
exportins in the nucleus bind to both cargo and Ran-GTP and then pass through the
NPC. In the cytoplasm, cargo is released when Ran GTPase activating protein 1 (Ran-
GAP1), which is located on the cytoplasmic side of the NPC, catalizes the hydrolysis
of Ran-GTP to Ran-GDP. Ran-GDP recycles back into the nucleus, where its guanine
nucleotide exchange factor (GEF) RCC1 exchanges the GDP for GTP to continue the
cycle. The gradient of Ran-GTP in the nucleus and Ran-GDP in the cytoplasm pro-
vides directionality to nucleocytoplasmic transport. Therefore, alterations in the ratio
of nuclear Ran or RanGAP1 can modify the rate and direction of active transport [128].
The first evidence of a mechanistic link between nucleocytoplasmic transport and
neurodegeneration came from studies from two independent laboratories focusing on
C9orf72-linked ALS/FTD [129, 130]. Both groups used transgenic fly lines expressing
G4C2 repeats, leading to RNA foci and DPR expression. By measuring the degree of
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eye degeneration, these studies identified members of the NPC and nucleocytoplasmic
machinery as modifiers of toxicity. Moreover, they validated their results using induced
pluripotent stem-cell-derived neurons (iPSN) from patients with C9orf72-related
disease. While in one of these studies they identified RNA export dysfunctions [129],
in the other they focused on protein transport and detected RanGap1 and Ran
mislocalization, together with defects in transport of a fluorescent reporter [130].
Most importantly, both studies presented the common finding that toxicity of RNA
transcripts or DPRs of the hexanucleotide expansion, can be rescued by altering
expression of specific NCT-related cellular proteins. Notably, two further screens
in Drosophila and in Saccharomyces cerevisiae indicated a role of NCT in C9orf72
expansion toxicity [131, 132]. Lastly, it was reported that the poly-dipeptide PR leads
to toxicity by clogging the nuclear pores [133].
Perturbations in NCT have been observed in HD as well. PolyQ expanded
HTT protein aggregates lead to mislocalization of Nup62, Nup88, and RanGAP1;
decrease in nuclear Ran protein, and change the localization of reporter proteins
between the nucleus and cytosol [134]. Moreover, an independent HD study detected
mislocalization of RanGap1 and Lamin B1 (a structural component of the nuclear
lamina), impairment of mRNA export, and mislocalization of the mRNA export factor
Gle1 [135]. It is important to mention that the findings from these two studies were
performed using a wide variety of systems, such as primary neuronal cells, iPSNs,
mouse models of HD, and postmortem patient material.
Finally, the most recent studies connecting NCT dysfunction to protein aggregation
put TDP-43 and tau aggregates in the picture. Regarding TDP-43, analysis of the
interactome of detergent-insoluble TDP-43 aggregates revealed an enrichment of
components of the NPC and the NCT machinery. Moreover, nuclear pore pathology
was validated in several cell types, as well as in ALS patient’s material [137]. As for
tau, it was shown that Nups with FG domains mislocalize from the nuclear membrane
and associate with cytoplasmic tau aggregates. Moreover, nuclei isolated from AD
brains were more permeable to large fluorescently tagged dextrans, demonstrating
alterations in the NPC diffusion barrier or the nuclear membrane. In addition, AD
patient brains presented lower nuclear to cytoplasmic ratio of Ran-GTP [138].
In summary, a potential unifying mechanism in NDs is that protein aggregates
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Figure 2.2: Nucleocytoplasmic transport impairment in NDs. Misfolded protein ag-
gregates have been shown to lead to mislocalization of several nucleocytoplasmic components,
such as export factors, Nups and RanGap1. Moreover, obstruction of the nuclear pores by
the aggregates, as well as deficient export of mRNA have been detected. Modified from [136].
or oligomers may sequester Nups, or other components of the NCT machinery, in a
non-functional manner (Fig.2.2). Since Nups can be very long-lived proteins and indi-
vidual subcomplexes are exchanged slowly over time, this can be especially detrimental
to post-mitotic cells such as neurons [128]. Intriguingly, it is yet an open question
whether common NCT pathways are disrupted by different protein aggregates, and
if therapeutic intervention to restore NCT, could reduce disease progression across
various NDs.
2.2.3 Trophic signaling dysregulation
Another commonality among several neurodegenerative diseases is the dysregula-
tion of neurotrophic factors and their receptors. The Neurotrophin (NTF) family of
proteins forms a class of functionally and structurally related proteins that regulate
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growth, differentiation and survival of central and peripheral neurons. The mammalian
NTF family comprises nerve growth factor (NGF), Brain-derived neurotrophic factor
(BDNF), neurotrophin 3 (NT-3) and neurotrophin 4/5 (NT-4/5). NTFs are initially
synthetized as pre-proproteins, cleavage of the signal peptide converts them into
pro-NTF, and further processing into mature NTF which are secreted from the
cell. All of these proteins act through two distinct receptor types: Trk receptor
tyrosine kinase family and neurotrophin receptor p75. In fact, different neurotrophins
show binding specificity for particular Trk receptors: NGF binds preferentially to
tropomyosin receptor kinase A (TrkA), BDNF and NT4 to TrkB, and neurotrophin
3 (NT3) to TrkC. The p75 receptor can bind to each neurotrophin as well as to the
pro-NTFs, recruits signaling adaptors and modulates Trk signaling [139].
Neurotrophin binding induces dimerization and autophosphorylation of Trk recep-
tors at multiple tyrosine residues, leading to the recruitment of different intracellular
signalling components and the activation of downstream pathways. Trk signaling
occurs through three principal tyrosine kinase-mediated pathways: the MAPK–ERK
pathway, the PI3K–AKT pathway and the phospholipase Cγ1 (PLCγ1)–PKC path-
way. The effects elicited through these signaling pathways predominantly promote cell
survival and differentiation. In contrast, ligand binding to p75 is generally thought
to induce death signals. For example, concomitant binding of pro-NGF to receptor
sortilin and p75, selectively promotes cell death [140]. However, binding of mature
NTFs to p75 can both promote cell death or increase cell survival, since its signaling
pathways are complex and the endpoint depends on several factors [139, 141, 142].
Dysregulation of NTFs has been reported in several neurodegenerative diseases. In
Alzheimer’s disease, increased levels of pro-NGF were detected throughout the human
brain, while decreased levels were detected only in the basal forebrain [143, 144, 145].
Moreover, a loss of the NGF receptor TrkA, but not of p75, was identified in the
basal forebrain and cortex of AD brains [146]. Importantly, in absence of NGF
signaling, cholinergic neurons (which are affected in AD) show shrinkage, reduction
in fiber density and downregulation of transmitter-associated enzymes (Choline
acetyltransferase (Chat) and Acetylcholinesterase (AChE)), resulting in a decrease
of cholinergic transmission [147]. Apart from the NGF and TrkA downregulation
observed in AD, binding of Aβ to p75 lead to apoptosis in cultured cells [148, 149].
Furthermore, BDNF and TrkB expression are also downregulated in cortex and hip-
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pocampus in AD [150, 151], even at pre-clinical stages [152]. Accordingly, enthorinal
administration of BDNF in rodent and primate models of AD was neuroprotective [153].
Moreover, a decrease in NGF, BDNF [154, 155], and Glial cell-derived neurotrophic
factor (GDNF) [156] has been shown in the substantia nigra of PD patients. However,
infusion of GDNF in PD patients brains did not ameliorate clinical symptoms in
clinical trials [157, 158].
BDNF and TrkB mRNA and/or protein levels are reduced in cortex, striatum and
hippocampus of HD patients as well as in animals models [159, 160, 161]. NT-3 mRNA
levels are as well greatly reduced in HD patients [159]. Beyond these reductions,
BDNF-TrkB signaling is disrupted in HD: mutant HTT impaired axonal transport
of BDNF [162, 163] and retrograde transport of TrkB receptors in striatal dendrites
[164]. Remarkably, TrkB receptors failed to properly engage postsynaptic signaling
mechanisms in HD mouse models and this dysfunction could be corrected by inhibition
of p75 or its downstream target PTEN [165].
Imbalances in neurotrophin signaling in neurodegeneration have been presented as
an attractive therapeutic target. However, the use of NTFs themselfs as therapy has
mostly failed, among other reasons, due to their short half-lives, inability to penetrate
tissue barriers, and activation of multiple receptors (where p75 activity can counteract
the benefit of Trk activity) [166]. Therefore, current strategies are focusing on the
generation of small molecules that target specific neurotrophin receptors [142].
2.3 Animal models of neurodegenerative diseases
Animal models of NDs have been briefly mentioned in section 1.1.2 and will be
further introduced here with a focus on mouse models. Generation of animal models of
NDs has been based on discovered mutated genes and genetic risk variants of disease.
These genetic guideposts, along with the identification of hallmark aggregating
proteins, have provided valuable insight into the pathophysiology and mechanisms of
neurodegenerative diseases. However, most individuals suffer from so called sporadic
forms of these disorders (i.e. have no known genetic cause) and the genetic form
of the disease does not always perfectly phenocopy the sporadic form. Already this
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discrepancy between models and affected humans, indicates that current models might
not be as perfect as desired. Therefore, conclusions taken out of animal studies should
not be overestimated [167, 168, 80].
AD is characterized by three hallmark pathologies: senile plaques (Aβ plaques),
neurofibrillary tangles, and hippocampal and cortical neurodegeneration [169]. Never-
theless, current mouse models do not reproduce the whole complexity of the pathology.
On one hand, there are mice that model amyloid deposition with Aβ aggregate accu-
mulation in senile plaques. These mice express AD-linked human mutations in APP,
PSEN1, and PSEN2. APP mutants either increase total Aβ or increase the relative
production of the more aggregation-prone Aβ42, this second case happening more
commonly. Moreover, co-expression of PSEN1/2 mutants with an APP transgene
drastically accelerates amyloid deposition. Interestingly, these mice present abnormal
dystrophic neurites, astrocytosis, microgliosis, and behavioral deficits such as memory
impairment [170, 171].
Alternatively, mice in which Aβ deposition is driven in absence of APP overex-
pression, including knock-in models, show plaques and gliosis, but subtle behavioral
abnormalities [172, 173]. Unfortunately, the biggest inconveniences of APP models
are the lack of tau pathology, robust neurodegeneration, and neurotransmitter abnor-
malities. Differences in neuroinflammatory responses and differences in brain aging
between mice and humans that might influence disease progression might explain
why APP transgenic mice do not fully recapitulate AD pathology. In accordance,
genetic ablation of endogenous tau in mice expressing human tau enhances tangle
formation [174], suggesting that endogenous mouse tau may interfere with the ability
of human tau to form tangles. Furthermore, another study investigated whether Aβ
species produced in mice are enough to drive full AD pathology in non-genetically
manipulated human neurons. To this aim, they generated a chimeric model by
xenografting human cortical precursor cells into the brains of newborn mice, which
integrated into the mouse host tissue. This chimeric model presented numerous
Aβ plaques and Aβ-associated neuroinflammation in the human transplant and,
importantly, the transplanted neurons showed remarkable signs of neurodegeneration
that were not detected in the mouse host brain or in transplanted PSC derived mouse
neurons. Thus, human neurons can respond to Aβ pathology differently than their
murine counterparts in vivo [175].
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On the other hand, genetically based models of tau pathology, unlike Aβ models,
exhibit overt neurodegeneration. However, these models are largely based on transgenic
overexpression of mutations that cause FTD-MAPT and it is not yet known how
relevant they are for AD tauopathy. Possibly, the hTau BAC mouse, which exhibits
more moderate tau pathology and neurodegeneration may model AD tauopathy better
[176]. Moreover, tau pathology could be enhanced by expressing both mutant human
tau and APP in multiple transgenic mice [177, 178], or by injection of aggregated
Aβ into a tau transgenic model [179]. Nevertheless, the mechanisms of tau-driven
neurodegeneration remain elusive and, it is uncertain, if synergistic interactions
between the two pathologies in mice are relevant to human disease [80].
PD is characterized by progressive loss of dopamine (DA) neurons in the substantia
nigra pars compacta and the presence of misfolded α-synuclein in Lewy bodies and
neurites [4]. Drug-induced mouse models of PD, such as the 6-hydroxydopamine
(6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) models, have
been widely used and lead to the key sysmptomatic treatment of PD, namely L-dopa
in combination with carbidopa. Unfortunately, trials to identify neuroprotective
therapies using these models have been futile [180]. However, the PD drug-induced
models are acute, rapid and do not model the molecular pathology of PD. They kill
DA neurons by mechanisms that may not be reflective of PD and produce a DA-loss
phenotype without any progressing evolution of pathology [167].
Alternatively, genetically-based mouse models of PD have been generated. Most of
them constitutively overexpress human WT α-syn (modelling SNCA multiplication),
or human mutant A53T or A30P α-syn (modelling missense SNCA mutations) under a
variety of different promoters. Despite accumulation of α-syn aggregates in the brain,
as well as motor and non-motor deficits, most models’ disadvantage is the lack of DA
neurons loss [167]. Surprisingly, only one BAC model overexpressing human WT α-syn
reported DA neuron loss [181]. Moreover, conditional overexpression of mutant α-syn
also lead to DA neuron degeneration [182].
To study other genetic forms of PD, several mouse models have been generated,
including transgenic models based on overexpression of LRRK2 mutants, and deletion
models of Parkin, PINK1 and DJ-1. Similarly as in α-syn models, these mice
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present only partial PD phenotypes and provide conflicting results in terms of DA
neurodegeneration [183]. In conclusion, in line with the AD models situation, PD
mouse models do not faithfully reproduce the predominantly sporadic human disease
and there is room for improved models.
Regarding ALS, patients exhibit loss of upper and lower motor neurons, leading to
fatal paralysis with respiratory failure. FTD is characterized by progressive degenera-
tion of the frontal and temporal lobes leading to dementia. Despite different clinical
manifestation, motor neuron degeneration and cognitive deficits can be concomitant
in patients [6]. Indeed, ubiquitinated TDP-43 inclusions were discovered to be a
common pathological hallmark in both ALS and FTD sporadic cases [46]. To date,
the mostly studied ALS models have been transgenic mice overespressing various
SOD1 mutations [184]. SOD1 mice develope cortical and spinal motor neurons loss,
denervation of the muscular junctions, aggregates of misfolded SOD1, and progressive
paralysis with reduced lifespan. Importantly, SOD1 mice have greatly contributed to
the identification of the non-cell autonomous component of ALS. It is been demon-
strated that glial cells surrounding the motor neurons contribute to their selective
destruction [185, 186, 187]. However, SOD1 models do not develop TDP-43 pathology.
Therefore, they represent good models for the minority of SOD1 genetic cases of ALS,
while mostly occurring cases, sporadic and with TDP-43 pathology, are not represented.
To investigate sporadic disease, a wide variety of TDP-43 mouse models have been
developed [188, 184]. These animals replicate partial disease phenotypes, not the full
ALS human phenotype. Moreover, important caveats for TDP-43 models are the
differences in RNAs bound by TDP-43 among different species, as well as distinct RNA
processing alterations elicited by TDP-43 between mice and humans. To complicate
things further, cell functionality might be highly dependent on well-balanced levels of
TDP-43, with modest changes in expression being detrimental for cells [189].
Currently, ALS and FTD research focuses on understanding disease mechanisms
linked to C9orf72. While two BAC models of hexanucleotide expanded C9orf72
developed RNA foci and RAN proteins, they did not show the neurodegenerative
or behavioral features of ALS/FTD [190, 191]. In contrast, a recent mouse model
presented decreased survival, paralysis, muscle denervation, motor neuron loss, anxiety-
like behavior, and cortical and hippocampal neurodegeneration, RNA foci, and RAN
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proteins [192]. These mice may be especially promising as a preclinical model in light
of recent advances in therapy development based on antisense oligonucleotides (ASOs)
[193]. In fact, ASO treatment against spinal muscular atrophy, a rare and often fatal
genetic disease affecting muscle strength and movement, has recently been approved
by the U.S. Food and Drug Administration [194]. Interestingly, administration of
ASOs in preclinical models of C9orf72 ALS/FTD has already shown promising results
[195] and further ASO testing in other models might be crucial for therapy development.
Finally, mouse models of HD aim to model progressive deterioration of cognitive
and motor functions, and the selective loss of GABAergic MSNs, as well as glu-
tamatergic cortical neurons that project to the striatum [39]. The R6/2 [76] and
N-171-82Q [196] mouse models develop acute HD-like phenotypes, since they express a
truncated N-terminal form of human mutant HTT. However, several compounds that
proved effective in R6/2 mice, did not have beneficial effects on patients [197, 198].
These results rose the concerns that truncated models could have the drawbacks of
loosing the natural genomic and protein context of the polyglutamine expansion,
leading to altered regulation, post-translational modifications and protein interactions
[199]. To overcome these concerns, full-length models, such as the YAC128 [200], the
BACHD [113] and the zQ175 [201, 202] were generated. Although the predictive value
in therapy development of the zQ175 model is still being investigated, the results
obtained with the truncated models suggest that confirmation in more than one model
will be necessary for robust conclusions in preclinical trials.
Overall, there is currently still room for improvement in the mouse models for
neurodegenerative diseases. Thus far, mice have had poor predictive value in the
development of symptomatic therapies and especially in the development of disease-
modifying therapies. However, even if other animal species, such as non-human
primates, would be better suited to model the aging component in NDs, the costs
and logistics of performing large-scale therapeutic trials in non-human primates
are tremendous. Moreover, mice models can be of great advantage to study basic
research questions regarding the development of the diseases, as to which misfolded
protein species are toxic and when, and why specific cell populations are particularly
vulnerable, potentially leading to novel therapeutic targets.
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2.4 Artificial β-sheet proteins as a model for amyloid-like ag-
gregation in neurodegeneration
The generation of a combinatorial library of de novo protein sequences that have
been rationally designed to form β-sheet secondary structures, has provided the
neurodegeneration field with an alternative tool to study mechanisms of amyloid-like
toxicity [203]. The sequence of these synthetic proteins consists of six β-strands (seven
residues each) containing a pattern of alternating polar and nonpolar aminoacids,
respectively linked by four-residue linkers (Fig.2.3 A). Moreover, transmission electron
microscopy revealed that these proteins self-assemble into fibrils (Fig.2.3 B) and can
bind the amyloid dye Congo red, similarly to natural amyloid proteins in neurodegen-
erative diseases [203].
Three of the de novo sequences, numbers 4, 17, and 23 in the library, have been
further employed in other studies, and referred to as β4, β17, and β23. A study in 2011,
overexpressed myc-tagged versions of the three artificial β-sheet proteins in Hek293T
cells. First, they observed that β4, β17, and β23 proteins formed aggregates that
could be labeled by the amyloid dye NIAD-4. Second, they detected time-dependent
β-sheet-induced cell death, while overexpression of a control α-helix forming protein
did not affect cell survival. Moreover, β-sheet proteins impaired cytoplasmic stress
response. Finally, proteins involved in key cellular pathways were identified as
interactors of the β-sheet proteins by quantitative proteomics [81]. Interestingly, this
study was followed by a report in 2016, in which it was described that cytosolic,
but not nuclear aggregation of artificial β-sheet proteins, impairs nucleocytoplasmic
transport of mRNA and proteins [204].
Artificial β-sheet proteins do not possess a biological function and therefore allow us
to study cytotoxicity mechanisms related to protein aggregation in a gain of function
situation. Since the function of endogenous proteins is not compromised, as might occur
with HTT in HD, or α-Synuclein in PD, research can be targeted at characterizing the
cellular consequences of protein aggregation. Therefore, during this thesis, we aimed
at exploiting the potential of artificial β-sheet proteins further to study neurodegener-
ation in a context more related to disease, such as primary neurons and a mouse model.
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Figure 2.3: Artificial amyloid-like aggregating β-sheet proteins. (A) The sequence of
artificial β-sheet proteins is composed of alternating polar and nonpolar aminoacids, form-
ing six β-strands. (B) Transmission electron microscope images depicting that the artificial
proteins self-assemble into amyloid-like fibrils. Adapted from [203].
2.5 Aims of the thesis
In order to uncover common mechanisms of toxicity in neurodegenerative diseases,
here I have utilized synthetic β-sheet proteins with three main aims:
• Analyzing the effects of aggregation of synthetic β-sheet proteins in neurons
cultured in vitro.
• Identifying β-sheet protein interactors and testing their potential role in common
mechanisms of cell toxicity due to protein misfolding.
• Studying the synthetic β-sheet protein’s aggregation effects in vivo by: gener-
ating and characterizing a reversible transgenic β23 mouse model of neurodegeneration.

3
Materials and Methods
3.1 Materials
3.1.1 Chemicals, reagents and kits
All chemicals, reagents, and kits were purchased from Merck, Sigma-Aldrich, Roth,
Roche, Thermo-Scientific,Bio-rad, Takara Bio, Qiagen, and Machery-Nagel.
3.1.2 Buffers
PBS
137 mM NaCl
2.7 mM KCl
4.3 mM Na2HPO4*7H2O
1.4 mM KH2PO4
TE
10 mM Tris Base pH=8
1 mM EDTA
50x TAE
2 M Tris acetate
50 mM EDTA
Western Blot buffers
Cell lysis buffer
50 mM Tris-HCl pH=7.4
150 mM NaCl
2 mM EDTA
1% Triton X-100
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+ cOmplete EDTA-free protease inhibitor cocktail tablet
+ PhosSTOP phosphatase inhibitor cocktail tablet
10X Tranfer buffer
30.3 g Tris Base
144 g Glycine
Fill to 1 L with MilliQ dH2O
To prepare 1 L of the working solution 1x Transfer buffer, mix the following reagents:
100 ml 10x transfer buffer + 200 ml Methanol + 700 ml MilliQ dH2O.
20X TBS-T
400 ml of 1 M Tris Base pH=8
600 ml of 5 M NaCl
20 ml Tween 20
To prepare 1 L of the working solution 1x TBS-T, take 50 ml of 20X TBS-T and add
950 ml of MilliQ dH2O.
6X Sample loading buffer
0.125 M Tris-HCl pH=6.8
20% Glycerol
4% SDS
2% β-mercaptoethanol
0.02% Bromphenolblue
4% stacking gel (mix for one gel)
3.05 ml dH2O
1.3 ml 0.5 M Tris pH=6.8, 0.4% SDS
0.65 ml 30% Acrylamyde/Bis solution
50 µl APS 10%
5 µl TEMED
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12% resolving gel (mix for one gel)
3.5 ml dH2O
2.6 ml 1.5 M Tris pH=8.8, 0.4% SDS
4 ml 30% Acrylamyde/Bis solution
50 µl APS 10%
5 µl TEMED
5X Running buffer
154.5 g Tris base
721 g Glycine
50 g SDS
MilliQ dH2O up to 10 L
Hash stripping buffer
20 mL SDS 10%
12.5 ml 0.5 M Tris-HCl, pH=6.8
67.5 ml dH2O
0.8 ml β-mercaptoethanol
Cell culture solutions and buffers
Primary neuronal culture
Borate buffer
3.1 g Boric acid
4.75 g Borax
Add to 1 L dH2O
Adjust to pH=8.5
Filter sterile with a 0.22 µm Bottle-top vacuum filter system (Corning)
Dissection medium
HBSS (Thermo Fisher)
+ 1% Pen/Strep (Invitrogen)
+ 10 mM Hepes (Biomol)
+ 10 mM MgSO4
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Culture medium
Neurobasal (Thermo Scientific)
+ 1% Pen/Strep (Invitrogen)
+ 1% L-Glutamine (Thermo Fisher)
+ 2% B27 supplement 50X (Thermo Fisher)
Hek293T culture for lentiviral production
Culture medium
DMEM Glutamax (+ 4.5 g/L D-Glucose, - Pyruvate)
+ 10% FBS (Sigma)
+ 1% G418 (Gibco)
+ 1% NEAA (Thermo Fisher)
+ 1% Hepes (Biomol)
TBS-5
50 mM Tris-HCl pH=7.8
130 mM NaCl
10 mM KCl
5 mM MgCl2
Filter sterile with a 0.22 µm Bottle-top vacuum filter system
Culture medium for CRISPR/Cas9 lentivirus production
2 ml DMEM
+ 10% FBS (Sigma)
+ 1% L-Glutamine
+ 10,000 units of Penicillin
+ 10 mg/ml of Streptomycin
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Interactome analysis buffers
Lysis buffer for Immunoprecipitation (IP)
0.25% NP40
5% Glycerol
50 mM Tris HCl
150 mM NaCl
DNAseI (5 µl/ml)
RNAseI (0.5 µl/ml)
+ cOmplete EDTA-free protease inhibitor cocktail tablet (Roche)
Beat digestion buffer
8 M Urea
40 mM Hepes pH=8
Endoproteinase LysC
10 mM DTT
Trypsin digestion buffer
Trypsin
50 mM Ammonium bicarbonate
55 mM Chloroacetamid
MTT solubilizer
50 g SDS 10%
225 ml Dimethylformamide 45%
Adjust to pH=4.5 with acetic acid
Fill up to 500 ml with water
Immunostaining on brain sections buffers
Blocking buffer
0.2% BSA
5% Donkey serum
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0.2% L-Lysine
0.2% Glycine
in PBS
Primary antibody solution
2% BSA
0.3% Triton 100-X
0.01% Sodium azide
in PBS
Secondary antibody solution
0.3% Triton 100-X
3% Donkey serum
0.01% Sodium azide
in PBS
Mowiol
6 g Glycerol
2.4 g Mowiol 4-88
stirr for 1 h
Add 6 ml dH2O
Stirr for 2 h
12ml Tris-HCl 0.2 M pH=8.4
Heat up solution to 50◦C in agitation until Mowiol 4-88 is completely dissolved.
Add antifading agent: 0.5% Propyl-galatete and stirr for 4 hs.
Centrifuge at 7500xg for 30 min to remove undissolved solids.
Aliquot and store at -20◦C.
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3.1.3 Plasmids and Crispr sgRNA
Plasmids
ID Insert Backbone Resistance Source
ID1 mCherry mCherry-N1 Kan Clontech
ID2 mycβ23mCherry mCherry-N1 Kan Hartl lab
ID30 mycβ4mCherry mCherry-N1 Kan Hartl lab
αS-829 pcDNA3.1 Amp Hartl lab
mycβ4 pcDNA3.1 Amp Hartl lab
mycβ23 pcDNA3.1 Amp Hartl lab
ID21 mycβ23-frt1-IRES-
frt-mCherry
pTRE3G Amp Cloned
ID22 mycβ23-frt2-IRES-
frt-mCherry
pTRE3G Amp Cloned
ID25 none pTRE3G Amp Clontech
ID53 Tet-On 3G (tTa) pCMV-Tet3G Amp Clontech
ID58 myc-b23-mCherry pTRE3G Amp Cloned
Lentiviral plasmids
ID Insert Backbone Resistance Source
ID32 myc-mCherry pENTR1A-164 Kan Cloned
ID33 mycβ4-mCherry pENTR1A-164 Kan Cloned
ID34 mycβ17-mCherry pENTR1A-164 Kan Cloned
ID35 mycβ23-mCherry pENTR1A-164 Kan Cloned
ID66 none pVsVg Amp D.Edbauer
ID67 none pSPAX2 Amp D.Edbauer
ID74 none pFhSynW2 Amp D.Edbauer
none pLenticrisprv2 Amp D.Hornburg
(Plasmid
]52961)
none pMD2.G Amp D.Hornburg
(Addgene
Plasmid
]12259)
ID68 mycmCherry pFhSynW2 Amp Cloned
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ID74 mycβ4-mCherry pFhSynW2 Amp Cloned
ID75 mycβ17-mCherry pFhSynW2 Amp Cloned
ID76 mycβ23-mCherry pFhSynW2 Amp Cloned
ID97 Flag-Girdin-eGFP pFhSynW2 Amp Cloned
Flag-GirdinFL pFhSynW2 Amp Cloned
ID98 Flag-eGFP pFhSynW2 Amp Cloned
ID99 myc-β23L63P-frt1-
IRES-frt-mCherry
pFhSynW2 Amp Cloned
ID100 myc-β23-frt1-IRES-
frt-mCherry
pFhSynW2 Amp Cloned
Table 3.1: Plasmids
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3.1.4 Primary antibodies
Primary antibodies
Antigen Host Company Reference
mCherry Goat Sicgen (Origene) AB0040-200
mCherry Rabbit Abcam ab167453
myc 9E10 Mouse Thermo Fisher 13-2500
myc Rabbit Cell signaling technology 2272
MAP2 Chicken Novus NB300-213
Cas9 (7A9-3A3) Mouse Cell signaling technology 14697
DDK (Flag) Mouse Origene TA-50011-100
Akt Rabbit Cell signaling technology 9272
Phospho-Akt (Ser473) Rabbit Cell signaling technology 4060
Erk1/2 Rabbit Cell signaling technology 9102
Phospho-Erk1/2 Rabbit Cell signaling technology 4376
Tubulin Mouse Sigma T9026
RanGap1 Mouse Santa Cruz sc-28322
Nup153 Mouse Abcam ab24700
Table 3.3: Primary antibodies
3.1.5 Secondary antibodies
Donkey serum and all secondary antibodies used for immunostainings were pur-
chased from Jackson Immunoresearch Laboratories. Secondary antibodies were used at
1:250 or 1:300 dilution.
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3.1.6 Mouse lines
Mouse lines
Line name Official name Comments
β23-frt1 TRE3G:mycb23frt1-IRES-
frt-mCherry
Unrecombined line. By crossing it to
a tTa driver line, double transgenic
mice express the artificial β-sheet pro-
tein β23 [203] with the point muta-
tion L63P and the fluorescent protein
mCherry as separately translated pro-
teins.
β23-frt2 TRE3G:mycb23frt2-IRES-
frt-mCherry
Second βb23 transgenic line. By cross-
ing it to a tTa driver line, double trans-
genic mice express the artificial β23
protein [203] and the fluorescent pro-
tein mCherry as separately translated
proteins. This line was generated but
not used for experiments.
CamKIIa-
tTA
B6;CBA-Tg(Camk2a-
tTA)1Mmay/J
Tet-Off tTa driver line [205].
Flpe Tg(ACTFLPe)9205Dym Flippase line used to generate the re-
combined line. Originally purchased
from Jax lab, reference MGI:2448985
[206].
β23-frt1-
mCherry
TRE3G:mycb23frt1-mCherry Recombined line. By crossing it to
a tTa driver line, double transgenic
mice express the artificial β-sheet pro-
tein β23 [203] with the point muta-
tion L63P and the fluorescent protein
mCherry as a fused proteins.
Table 3.4: Mouse lines
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3.1.7 Genotyping primers
Primers
ID Name Sequence 5’→3’ PCR
14 b23-1-For TTTCCGTACCACTTCCTACCCTCGT b23-1, Recom
15 b23-1-Rev GCCTGCAAAGGGTCGCTACAGAC b23-1
16 b23-2-For GGGCCTCGGTACACATGCTTTAC b23-2
17 b23-2-Rev CAAGTAGTCGGGGATGTCGGC b23-2, Recom
23 CamK-wt-For CAAATGTTGCTTGTCTGGTG Camk
24 CamK-wt-Rev GTCAGTCGAGTGCACAGTTT Camk
25 CamK-tg-For CGCTGTGGGGCATTTTACTTTAG Camk
26 CamK-tg-Rev CATGTCCAGATCGAAATCGTC Camk
55 NEFH-wt-For CTAGGCCACAGAATTGAAAGATCT Camk
56 NEFH-wt-Rev GTAGGTGGAAATTCTAGCATCATCC Camk
57 NEFH-tg-For CTCGCGCACCTGCTGAAT Camk
58 NEFH-tg-Rev CAGTACAGGGTAGGCTGCTC Camk
35 Flp-For CTAATGTTGTGGGAAATTGGAGC Flpe
36 Flp-Rev CTCGAGGATAACTTGTTTATTGC Flpe
Table 3.5: Genotyping primers
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3.2 Methods
3.2.1 Agarose gel electrophoresis
Agarose gels were prepared by dissolving agarose in 1X TAE buffer, ususally to
1% concentration. If DNA fragments to separate were over 10 Kb, 2% gels were
prepared. The mix was boiled in a microwave for 3-5 min until agarose was fully
dissolved. After cooling down, Ethidium bromide (Roth) was added to a concentration
of 0.5 µg/µl. Then, the solution was poured into a plastic tray for polymerization
at RT. DNA was separated on the gel based on size by electrophoresis, at a voltage
of 100 – 180 V. DNA was visualised by UV light using a Gel Doc XR+ machine (Biorad).
3.2.2 Plasmid DNA generation
All enzymes were purchased from New England Biolabs, except for Pfu polymerase,
which was purchased from Promega. All primers and sequencing reactions were
purchased from Eurofins genomics.
Cloning
DNA plasmids were cloned either via classic restriction and ligation, or using
the Infusion cloning kit (Takara bio). Initially, the backbone vector was restricted
overnight with two different restriction enzymes. Then, loading buffer was added to
the reaction mix. To only isolate the restricted vector and discard the undesired DNA
fragments, the mix was run on a 1-2% agarose gel and the band of restricted vector was
excised. GeneRuler 1 kb was used to check for the correct band size. After excision,
vector DNA was extracted and purified using the NucleoSpin gel and PCR clean-up
kit. Finally, DNA concentration was measured with a Nanodrop (Peqlab, Nanodrop
1000) and the software NanoDrop 1000 3.7.1 (Thermo Scientific).
PCR with Pfu polymerase was used to amplify the insert DNA. PCR products
were run on a 1% agarose gel and bands were excised. Then, DNA was extracted
and purified as mentioned above. If classic cloning was used, the insert was restricted
overnight with the same restriction enzymes used to restrict the vector. Next, restricted
DNA insert was purified using the Nucleospin kit. Finally, 50 ng of purified backbone
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vector were ligated with 250-500ng of purified insert, according to 1:5 or 1:10 ratio
vector:insert. The ligation reaction was performed overnight at 16◦C using T4 ligation
enzyme. Alternatively, if Infusion cloning was used, the restriction step was skipped
and ligation was performed following the manufacturer’s instructions.
Transformation of DH5α electrocompetent cells
Homemade electrocompetent DH5α E.coli bacterial cells were used for transfor-
mation via eletroporation. 100-500 ng of DNA were added to 50 µl of bacteria. The
mix was transferred to a prechilled cuvette (Gene Pulser Cuvettes, 0.2 cm electrodes,
Bio-Rad) and electroporation was performed with two pulses of 25 µF (Bio-Rad, Puls
Controller). Next, 250 µl of LB medium were added to the cells and the whole volume
was transferred to a round-bottom 14 ml Falcon tube. After 1 h incubation at 37◦C
and 225 rpm, transformed cells were streaked on either Amp or Kan-containing agar
plates and incubated overnight at 37◦C.
Isolation of plasmid DNA
Plasmid DNA was isolated from single bacterial colonies. First, bacteria were
expanded overnight at 37◦C in 300 ml LB medium containing either 100 µg/ml of
Amp or 30 µg/ml of Kan. Afterwards, DNA isolation was performed according to the
manufacturer’s instructions with the Nucleobond kit. DNA was resuspended in TE
buffer to a working concentration of 1 µg/µl. Finally, plasmid samples were sent for
sequencing and results were aligned with the expected sequence using the Megalign
software, included in the Lasergene core suite software.
3.2.3 CRISPR/Cas9 design and cloning
Construct design and generation was modified from the Zhang lab protocol
provided under https://www.addgene.org/crispr/zhang. Oligos were designed for
BsmBI golden gate cloning. Suitable guides were selected via the chopchop online tool
(https://chopchop.rc.fas.harvard.edu/). The retrieved 20 bp sequences were inserted
(without PAM) into 5’-GT CGTCTC C CACC G– 20 bp –GTTT C GAGACG TG-3’.
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The resulting sequences and the respective reverse complements were ordered.
For oligo annealing 1 µl (100 µM) of forward and reverse oligos were added to 98
µl TE buffer and incubated for 5 min at 95◦C. Afterwards, the mix was cooled down
for 2 h to RT. Annealed oligos were stored at -20◦C.
For golden gate cloning reaction, 50 ng of vector lentiCRISPRv2 were mixed with
2 µl T4 ligase buffer (Promega), 1 µl T4 DNA ligase (Promega), 1 µl 10 U/µl BsmBI
(NEB) and 1 µl of the annealed oligos from a 1:10 dilution in dH2O. dH2O was added
to a final volume of 20 µl. The reaction proceeded in a Thermocycler (Bio-Rad) and
the PCR cycles were: 1) 5min at 37◦C, 2) 10 min at 16◦C, 3) 5 min at 55◦C, 4) 5 min
at 80◦C. Step 1 and 2 were repeated 10 times. The reaction mix was either stored at
4◦C or directly used for transformation.
RecA-deficient (recA1) bacteria electrocompetent DH10b were transformed as
above with 1 µl of the golden gate cloning reaction product and streaked on Amp
plates. Single colonies were selected and expanded. Plasmid DNA was isolated by
miniprep and sequenced using the U6 primer.
3.2.4 Generation of an inducible stable cell line
The Tet-On 3G Inducible Expression System (Clontech, Cat.No. 631168) was used
to generate an inducible double-stable cell line expressing mycβ23mCherry. First,
a stable cell line expressing the Tet-On 3G transactivator was created. To do so,
Hek293T cells were seeded on a 30 cm dish and transfected with 2 µg of plasmid
pCMV-Tet3G (ID53) when near confluent. After 48 hrs, cells were split into 4 x 10
cm dishes. After an additional 48 hs, G418 (Gibco) was added at 500 µg/ml. Medium
with fresh G418 was replaced every 2-4 days for 2 weeks. Next, a total of 24 individual
colonies were transferred into separate wells of a 24-well plate using cloning cylinders
(Sigma). Clones were furhter cultured in a maintenance concentration of G418 100
µg/ml. When confluent, cells from each well were split into three wells of a 6-well plate
for testing and maintenance. One well was used for maintenance, and the other two
were transfected with 5 µg of pTRE3G-Luc. After 4 hs, the culture medium of one
well was replaced with fresh medium containing 500 ng/ml Dox (Sigma), the other well
received Dox-free fresh medium. Finally, after 24 hs, luciferase activity was measured
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and the fold induction calculated (+Dox RLU/-Dox RLU). The clone with the highest
fold induction (clone 11, in this case) was selected for expansion, which was done in
maintenance concentration of G418 100 µg/ml, and a stock of the pCMV-Tet3G stable
cell line was cryopreserved.
Subsequently, Tet3G-expressing cells were cultured in a single well of a 6-well
plate and always kept in G418 100 µg/ml. When near confluent, the well was
cotransfected with 2 µg of plasmid ID58 (pTRE3G-mycβ23mCherry) and 100 ng
hygromycin linear selection marker. After 48 hs, cells were split into 4 x 10 cm
dishes. After an additional 48 hs, hygromycin was added at 100 µg/ml. Medium
was replaced with fresh complete medium plus hygromycin every 2-4 days for two
weeks. As before, a total of 24 individual colonies were transferred into separate
wells of a 24-well plate using cloning cylinders. Clones were cultured in maintenance
concentrations of G418 and hygromycin, 100 µg/ml and 50 µg/ml, respectively.
When confluent, cells from each well were split into three wells of a 6-well plate for
testing and maintenance. 500 ng/ml Dox was added to one of the wells and mCherry
fluorescence and aggregate presence was assessed at the fluorescent microscope after 48
hs. The clone with the highest mCherry intensity (clone 5, in this case) was selected for
expansion and a stock of the double-stable cell line mycβ23mCherry was cryopreserved.
Cryopreservation was performed using cryovials (Nunc) containing cells in 50%
DMEM, 40% FBS, 10% DMSO. Cryovials were placed at -80◦C in freezing containers
(Nalgene) containing isopropanol. For long-term storage, cryovials were transferred to
liquid nitrogen tanks.
3.2.5 Lentivirus production in Hek293T cells
Hek293T cells for lentiviral packaging were purchased (Lenti-X 293T cell line,
Takara) and expanded in Hek293T culture medium for lentiviral production (see 3.1.2).
Then, a cellular stock of passage 3-4 Hek293T cells was generated by cryopreserving
vials containing approximately four millions cells in 50% DMEM, 40% FBS, 10%
DMSO. Stock was stored in liquid nitrogen.
To produce a lentiviral batch, one vial of Hek293T cells was thawed at 37◦C. Cells
were transferred into 5 ml of Hek293T culture medium and centrifuged for 5 min at
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800xg. The cell pellet was resuspended in 10 ml of Hek293T culture medium and
cultured in a T75 cm2 flask (Falcon). Next day, medium was completely exchanged.
Following day, when cells had usually reached 80% confluency, they were trypsinized
and passaged to a T175 cm2 flask (Falcon). One day later, cells were trypsinized and
passaged to a three-layered 525 cm2 (Falcon). Subsequently, one day later, cells were
trypsinized and four T75 cm2 flasks containing 5.7 million cells each were seeded. At
this point, G418 was removed from the culture medium composition. Next day in the
evening, the three of the flasks were transfected for virus production. Transfection
reaction mix was prepared according to the following table:
Transfection mix for 3xT75 cm2
Mix A
Reagent Quantity
LTR-vector (pFhSynW2) 18.6 µg
pSPAX2 11 µg
pVsVg 6.4 µg
DMEM without FBS 1500 µl
Mix B
Reagent Quantity
TransIT-Lenti transfection reagent
(Mirus)
108 µl
DMEM without FBS 1500 µl
Add mix A to mix B
Table 3.6: Transfection mix for lentiviral production
The transfection mix was incubated for 20 min at RT and, meanwhile, cell medium
was exchanged. Then, 1 ml transfection mix was added to each flask, leaving the
transfection overnight. In the morning on the following day, cells were checked for
fluorescence (only if the LTR vector contained a fluorescent protein sequence), washed
once with prewarmed PBS and fresh medium was added. After 48 hs, culture medium
containing the viral particles was collected, pooling the three flasks into one Falcon
tube. To remove cells debris, centrifugation for 10 min at 1200xg was performed. Then,
the supernatant was filtered through 0.45 µm pore size filters using 50ml syringes,
and transferred to Utra-clear centrifuge tubes (Beckman). Finally, cell medium was
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centrifuged at 100,000xg for 2 h with a centrifuge Avanti JXN-30, rotor JS-24.38
(Beckman). Supernatant was discarded and the lentivirus pellet resuspended in 100 µl
TBS-5 buffer. After aliquoting, virus was stored at -80◦C.
Lentivirus production for CRISPR/Cas9 expression
For lentivirus production 1.2*106 Hek293T cells were seeded per well into 6-well
plates and grown in culture medium for Crispr/Cas9 lentivirus production. Six hours
later, cells were transfected with Lipofectamine2000. Transfection reaction mix was
prepared according to the following table:
Transfection mix in 6-well plates
Mix A
Reagent Quantity
OptiMEM 100 µl
pMD2.G 1 µg
psPAX2 1.5 µg
pLentiCRSPRv2 2.2 µg
Mix B
Reagent Quantity
Lipofectamine2000 10 µl
OptiMEM 100 µl
Add mix A to mix B
Table 3.7: Transfection mix for Crispr/Cas9 lentiviral expresssion
Solution A and B were combined, incubated 30 min at RT, and added to the cells.
16 hours later, medium was removed and 3 mL fresh cell medium with 30% FBS was
added. Cell medium containing virus was harvested after 24 h and stored at -80◦C.
In order to concentrate and rebuffer the viruses in neuron compatible medium they
were precipitated according to Kuttner et. al (2009). [207]. In short, virus aliquots
were thawed and centrifuged for 5 min at 16,000xg and 4◦C. The supernatant was
mixed 1:1 with precipitation buffer (for 500 µl supernatant: 170 µl of 50% PEG600
(final 8.5%) , 75 µl of 4M NaCl (final 0.3M), 255 µl PBS) and incubated at 4◦C for 4
h. Samples were gently agitated every 20 min. Next, samples were centrifuged for 10
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min at 7,000xg and 4◦C. The supernatant was discarded and 100 µl of neuronal culture
medium was added to the pellet containing the virus. All steps for lentivirus produc-
tion for Crispr/Cas9 expression were performed by Daniel Hornburg and Martin Dodel.
3.2.6 Primary neuronal culture
Coating
The surface of culture wells was coated previous to neuronal seeding to facilitate
attachment and growth. First, sterile Poly-D-lysine 1 mg/ml in borate buffer solution
was used for 2-4 h. After 3-4 times PBS washing, laminin 5 µg/ml in PBS solution was
added for further 2-4 h. Finally, one more PBS washing was done before cell seeding.
If neurons were to be used for immunocytochemistry, they were seeded onto 13 mm
glass coverslips placed in 24-well plates. Coverslips were sterilized overnight at 180◦C
and were coated as above.
Neuronal dissociation protocol
Primary cortical or hippocampal neurons were dissociated from E15.5 or E17.5
CD-1 wt embryos. First, pregnant CD-1 females were sacrificed by cervical dislocation
and the uterus was placed in prechilled PBS. Then, the uterus was transferred into ice
cold dissection medium and embryos were dissected out of it. Next, embryos were de-
capitated and heads transferred into fresh dissection medium. Afterwards, whole brains
were dissected out of the skull and neocortices were excised out. Finally, meninges were
removed and cortex or hippocampus were dissected and placed in prewarmed Trypsin
(Gibco) with 1% DNAseI 0.05% for 20 min at 37◦C. Next, trypsin activity was stopped
by adding Neurobasal supplemented with 0.05% FBS. The medium was discarded
and prewarmed cell culture medium was added to the tissue. After homogenization
by pipetting, cells were pelleted at 130xg for 5 min and resuspended in prewarmed
culture medium. After cell counting using a Neubauer chamber (Brand), dissociated
primary neurons were seeded on 96, 24, 12 or 6 well-plates (Costar). Cortical neuron
seeding density was 100,000 cells/cm2 and hippocampal neuron seeding density was
80,000 cells/cm2. Neuronal cultures were maintained at 37◦C, 5% CO2.
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3.2.7 Neuronal transfection with calcium phosphate
Primary neurons were transfected at 10 Days in vitro (DIV) with a modified
protocol from Jiang and Chen [208]. Briefly, DNA was mixed with dH2O and CaCl2
was added dropwise to the solution. This mix was added dropwise to a second
tube containing 2x HBS and incubated at RT for 30-45 min. Next, coverslips were
transferred into a new culture plate, containing prewarmed fresh neuronal culture
medium. Subsequently, 30 µl of transfection mix was added dropwise to each well
and incubated for 3.5 h. Then, cells were washed once with culture medium that
had previously been acidifed in 10% CO2, and incubated for 30 min in the acidified
medium at 37◦C, 5% CO2. Finally, coverslips were transferred back to their original
culture medium.
3.2.8 Lentiviral transduction
Virus were thawed and immediately added to freshly prepared neuronal culture
medium. A fifth of the culture medium was removed and the equivalent volume of
virus-containing medium was added to neurons. Usually, 1 µl/cm2 of virus was added,
but this amount was at times adjusted to match protein expression levels among
different constructs.
3.2.9 BDNF treatment of primary hippocampal neurons
E17 primary hippocampal neurons were cultured in 12 well plates. At 10+3 and
10+4 DIV, respectively, recombinant human BDNF (hBDNF) (R and D Systems) was
administered to neurons. To do so, cell medium was removed, and cells were washed
once with warmed-up PBS. Then, hBDNF diluted in warmed-up neurobasal medium
without additives was added to the neurons in concentrations of 0, 5 ,15, 25, and 50
ng/ml. Cells were incubated for 30min at 37◦C, 5% CO2. After incubation, cells were
washed once with PBS and lysed in 200 µl lysis buffer. Lysates were stored at -20◦C
for further use.
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3.2.10 Western blot
First, cell culture medium was removed and cells washed twice with ice-cold PBS.
For cell lysis, 100 µl/cm2 prechilled cell lysis buffer was added to cells and incubated
for 20 min at 4◦C. Cell scrapers (Starstedt) were used to facilitate cell detachment and
lysate collection. Lysates were stored at -20◦C until further use.
To perform the western blot, samples were centrifuged for 10min at 4,000xg and
4◦C to separate the soluble cell lysate from cell debris. Supernatants were collected in
prechilled Eppendorf tubes. Next, equal amounts of the cell lysates were transferred to
another Eppendorf tube containing 6x sample loading buffer. Tubes containing sample
and loading buffer were boiled for 5min at 95◦C on a heating block (Eppendorf).
Acrylamyde gels were handcasted using Bio-Rad glassplates and consisted of a 12%
resolving gel and a 4% stacking gel. When solidified, gels were placed into the running
chamber containing 1X running buffer. After boiling, samples were loaded on the gel
and protein standards (Bio-Rad) were included in one well for protein size reference.
If there were wells with no sample, 5 µl of sample loading buffer were added to
prevent samples from running unevenly. First, gels were run for 20 min at 100 V and,
afterwards, at 120 V until the front run out.
After running, stacking gel was removed and the resolving part was soaked in 1X
transfer buffer for 10 min. Meanwhile, mini trans-blot filter paper (Bio-Rad) was
soaked as well in 1X transfer buffer. PVDF membrane (Thermo Fisher) was activated
in methanol, washed twice in MilliQ dH2O, and equilibrated in 1X transfer buffer. To
transfer proteins from the gel to the PVDF membrane, filter papers, PVDF membrane,
and gel were assembled into a so called sandwich and transference was performed using
a Trans-Blot Turbo transfer system (Bio-Rad). Transference parameters were 25 V,
2.5 A for 40-50 min.
Next, membrane was blocked using 3% BSA, 5% dried milk (Roth) in TBS-T for
1 h at RT on a shaker. After rinsing twice with 1x TBS-T, primary antibody was
added and incubated for 2 days overnight at 4◦C on a shaker. Primary antibodies were
diluted 1:1000 in 3% BSA in TBS-T, 0.01% Sodium azide (SA). Then, membranes
were washed three times for 10 min in 1X TBS-T and secondary antibody was added.
Secondary antibodies were diluted 1:5000 in 5% dried milk in TBS-T and applied for
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2 h at RT on a shaker. Finally, membranes were washed three times for 10 min in 1x
TBS-T, ECL detection reagent (GE Healthcare) was added on the membrane, and
substrate reaction detection was performed using a Peqlab Fusion Fx7.
Immunoprecipitation for interactome analysis
Cortical neurons were washed three times with ice-cold PBS and 250 µl of prechilled
lysis buffer were added per well. Lysates were incubated for 10 min at 4◦C, collected
in prechilled Eppendorfs and stored at -20◦C. For the mCherry immunoprecipitations,
we used the Thermo Scientific Pierce Protein G Agarose (10 ul/100 ug IgG). First, to
block non-specific binding, serum samples containing IgG were incubated with Protein
G agarose for 1 hour. Then, the neuronal lysates were loaded to the IgG-protein G
Agarose and incubated for 4 h. Non-IgG and non-antigen components were discarded
from the sample by washing (0.1% NP40, 5% Glycerol, 50 mM Tris HCl, 150 mM
NaCl). Next, for the beat digestion, we used beat digestion buffer. Later, samples
were incubated for 1 hour with Trypsin digestion buffer (Trypsin, 50 mM ABC, 55 mM
CAA) and washed with quenching buffer (2 M Urea, 50 mM thiourea). Trypsin was
added for overnight digestion. Finally, ACN and TFA were added to stop the reaction.
3.2.11 Immunocytochemistry
Cell culture medium was removed and cells washed once with ice-cold PBS.
Fixation was performed by adding 4% PFA in PBS for 20 min. Next, cells were washed
once more with PBS and stored in PBS at 4◦C until further use.
After cell fixation, remaining free groups of PFA were blocked with 50mM Am-
moniumchloride in PBS for 10 min at RT. Cells were rinsed once with PBS and
permeabilized with 0.25% Triton X-100 in PBS for 5 min. After permeabilization,
cells were washed three times for 5 min each with PBS. Then, blocking was performed
for 30 min at RT. Blocking solution contained 2% BSA (w/v)(Roth) and 4% donkey
serum (v/v) in PBS. After the blocking step, coverslips were transferred one by one
to a light-protected humid chamber and placed on parafilm. Immediately after, each
coverslip was covered with 50 µl of diluted primary antibody in blocking solution.
After 1 h incubation in primary antibody, cells were washed three times for 5 min
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each with PBS. Then, each coverslip was covered with 50 µl of 1:250 diluted secondary
antibody in blocking solution. Secondary antibody solution contained 1:2000 diluted
Dapi to stain cell nucleus. Finally, coverslips were washed three times for 5 min each
with PBS, dipped in dH2O and mounted on menzer glass slides using Dako fluorescence
mounting medium. Slides were stored in darkness overnight at RT for the mounting
medium to dry, followed by storage at 4◦C for further use.
Neuronal morphology analysis
Coverslips were immunostained against mCherry and imaged with a 40x objective.
Maximum intensity projections were analyzed. First, cell morphologies were semi-
automatically traced with the Simple Neurite Tracer plug-in of ImageJ. Importantly,
cell morphologies were traced in a blinded way. Then, complexity of the traced neurons
was quantified with the Sholl analysis plug-in of ImageJ. To that aim, a custom-made
ImageJ macro was created to automatically do the Sholl analysis in batch (by Daniel
del Toro Ruiz).
3.2.12 MTT cell viability assay
MTT reagent was purchased from Sigma-Aldrich. MTT assays were performed on
cells cultured in 96-well plates. First, cell medium was exchanged for 100 µl of fresh
medium. Then, 20 µl of 5 mg/ml MTT in PBS were added to each well. The plate was
placed back in the incubator for 2-4 h at 37◦C, 5% CO2 for the cells to metabolize MTT
(yellow) into formazan crystals (purple). Subsequently, 100 µl solubilizer solution were
added to each well to dissolve the crystals. The plate was incubated overnight at 37◦C,
5% CO2. Finally, absorbance was measured at 570 nm. Each condition was measured
in triplicates and absorbance values averaged for each experiment. A condition with
only medium was included in all experiments. The average absorbance value for the
medium condition was subtracted from all conditions in the experiment.
3.2.13 Generation of the TRE3G:mycβ23frt-IRES-frt-mCherry mouse line
To generate inducible transgenic mice expressing β23, a Tetracycline (Tet)-
responsive expression system was used. Two mouse lines with two different frt were
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generated. In one line, referred as β23frt1, the frt sequence before the IRES was placed
in frame to code for the following aminoacid sequence: KFLFSRKYRNF. In the other
line, referred as β23frt2, the frt sequence before the IRES was placed in frame to code
for the following aminoacid sequence: SSYSLESIGT. For both lines, the frt after the
IRES corresponded to frt1.
Plasmid DNA generation was done in several steps. First, IRES-frt-mCherry insert
sequence was restricted out of plasmid ID16 with EagI and MluI restriction enzymes.
pTRE3G vector (Clontech) was obtained and linearized with EagI and MluI as well.
Then, insert was ligated into the vector and DNA was sequenced (Step1). Next,
mycβ23frt1/2 insert sequence was amplified by PCR from plasmids ID17 and ID18,
adding an ApaI restriction site at 5’end and an EagI restriction site at 3’end. This
second insert was restricted with EagI first, followed by ApaI restriction. The plasmid
generated in step 1, was restricted with EagI first, followed by ApaI as well. Subse-
quently, restricted mycβ23frt1/2 inserts were ligated into the linearized vector from
step1 and DNA was sequenced (step2). The final vectors were purified with endotoxin
free (EF) maxi prep kit. The vector containing TRE3G:mycβ23frt1-IRES-frt-mCherry
was termed ID21. The vector containing TRE3G:mycβ23frt2-IRES-frt-mCherry was
termed ID22.
The DNA fragments to be used for pronuclear injection were obtained after XhoI
and SapI restriction of ID21 and ID22. The fragments were extracted from an agarose
gel using JetSorb gel extraction kit (Genomed) and subsequently filtered using PVDF
0.45 µm Ultrafree MC GV filters (Millipore). Purity of the DNA was checked by gel
electrophoresis. Final DNA was given to the transgenic service at a concentration
of 50-100 ng/µl. The transgenic service conducted the pronuclear injections and
provided us with several mouse founders. Then, tail biopsies of these founders were
used to detect transgene integration by PCRs b23-1 and b23-2. Out of these founders,
only one showed germline transmission and expression of the transgene from ID21
(β23-frt1 1056). In addition, one showed germline transmission and expression of
the transgene from ID22 (β23-frt2 1401). For this thesis, all work with the β23
transgenic mouse was performed with the β23-frt1 1056 line. Of note, it has been de-
tected that mice of the 1056 line express a mutated form of the β23 protein, β23L63P,
in which the last lysine aminoacid in the transgene sequence was exchanged by a proline.
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3.2.14 Mouse colony maintenance
Mice were housed at the animal facility of the Max Planck Institute of Biochemistry
(Martinsried, Germany) under Specific-pathogen-free (SPF) conditions and with ad
libitum access to food and water. Mice were maintained accordingly to local animal
welfare guidelines (Regierung von Oberbayern). Female and male mice were used for
the experiments.
All mice used in this thesis were heterozygous. β23 mice were kept in a C57BL/6NRj
genetic background. To induce β23 expression in the forebrain, mice were crossed
to CamKIIα:tTa mice, which were obtained from the Jackson Laboratory, and
originally published by Mayford et. al (1996). CamKIIα:tTa mice were kept in a
mixed CBAxC57BL/6NRj background. Therefore, β23;CamKIIα:tTa mice were in a
25%CBA, 75%C57BL/6NRj genetic background.
To induce β23 expression in the whole CNS, mice were crossed to NEFH:tTa
mice, which were obtained from the Jackson Laboratory, and originally published by
Walker et. al (2015). NEFH:tTa mice were backcrossed onto C57BL/6NRj genetic
background for at least four generations. Therefore, β23;NEFH:tTa mice were in a
pure C57BL/6NRj genetic background.
Mice which express the construct mycβ23frt1-IRES-frt-mCherry, therefore leading
to separate translation of β and mCherry, are referred to as unrecombined. To excise
out the IRES cassette, β23-frt1 line was crossed to a Flippase line (FLPe), obtained
from the Jackson Laboratory. The progeny of these mice were genotyped to detect
presence of the construct mycβ23frtmCherry, and absence of mycβ23frt1-IRES-frt-
mCherry. Mice in which recombination had worked, were further kept and maintained
in C57BL/6NRj background. Therefore, mice which expressed mycβ23frtmCherry as
a fusion protein are referred to as recombined.
Doxycyclin administration
β23;CamKIIα:tTa mice were administered doxycycline from embryonic day 0
until postnatal day 21. Females were given 2mg/ml doxycycline in the drinking
water during the whole pregnancy and until pups were weaned. The antibiotic was
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dissolved in 5% sucrose water and kept in dark drinking bottles to prevent light ex-
posure. Mice had ad libitum access to drinking and bottles were exchanged once a week.
β23;NEFH:tTa mice were administered doxycycline from embryonic day 0 until
postnatal day 21. Females were given 200 mg/kg doxycycline in food pellets (Snniff)
during the whole pregnancy and until pups were weaned. Mice had ad libitum access
to food and pellets were exchanged once a week.
3.2.15 Mouse getnoyping protocols
A tail biopsy of 1-2 mm of each mouse was lysed in 100 µl of 50 mM NaOH for three
cycles of 15min at 95◦C, vortexing in between each cycle. Next, 10 µl of 1.5M Tris-HCl
pH=8.8 were added for neutralization. DNA containing-solution from lysed tails was
used for genotyping by polymerase chain reaction (PCR). A PCR master mix was
prepared on ice (47-49 µl) and mixed with the respective DNA samples (1-3 µl). PCRs
were performed in a Thermocycler (BioRad) and products were run on 1% agarose gels.
The PCR protocols are depicted in the following tables (Tables 3.8, 3.9, 3.10, 3.11,
3.12). All unrecombined mice were genotyped twice using two different PCR protocols:
b23-1 and b23-2. All recombined mice were genotyped using the Recom PCR protocol.
Genotyping to identify CamKIIα:tTa-positive mice was performed using the CamK
PCR protocol. Genotyping to identify NEFH:tTa-positive mice was also performed
using the CamK PCR protocol. Flippase-positive mice were identified using the Flp
PCR protocol.
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b23-1 PCR protocol
Step Temperature
(◦C)
Time Go to
1 95 5 min
2 95 1 min
3 62 30 s
4 72 1 min Go to step 2, 34x
5 72 5 min
6 12 forever
PCR product 618 bp
Table 3.8: b23-1 PCR protocol
b23-2 PCR protocol
Step Temperature
(◦C)
Time Go to
1 95 5 min
2 95 1 min
3 60 30 s
4 72 1 min Go to step 2, 34x
5 72 5 min
6 12 forever
PCR product 427 bp
Table 3.9: b23-2 PCR protocol
64 3. Materials and Methods
Recom PCR protocol
Step Temperature
(◦C)
Time Go to
1 95 5 min
2 95 1 min
3 60 1 min
4 72 1 min Go to step 2, 34x
5 72 5 min
6 12 forever
PCR product 600 bp
Table 3.10: Recom PCR protocol
CamK PCR protocol
Step Temperature
(◦C)
Time Go to
1 94 3 min
2 94 30 s
3 57 1 min
4 72 1 min Go to step 2, 34x
5 72 2 min
6 12 forever
Two PCR products: 450 bp (transgene) and 200 bp (wt positive control)
Table 3.11: CamK PCR protocol
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Flp PCR protocol
Step Temperature
(◦C)
Time Go to
1 94 1 min
2 94 1 min
3 60 1 min
4 72 1 min Go to step 2, 34x
5 72 1 min
6 12 forever
PCR product ∼500 bp
Table 3.12: Flp PCR protocol
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3.2.16 Histology
Transcardial perfusion
Mice were anesthetized first with isofluorane (cp-pharma) and then with ke-
tamine/xylazine in saline (16% ketamine (Medistar), 8% xylazine (Medistar)). They
were first perfused using a Minipuls 3 peristaltic pump (Gilson) with ice-cold PBS
for 3-4 min, followed by 6-8 min of ice-cold, freshly prepared 4% PFA. Brains were
extracted and post-fixed for 24-48 h in 4% PFA at 4◦C. For storage, brains were placed
in 0.05% sodium azide in PBS at 4◦C. Of note, after perfusion, brains ought not to be
embedded, since this inhibits myc staining to detect β23. In our hands, agarose and
gelatin/albumin embedding prevented myc antibodies from binding. Other embedding
materials have not been used.
Immunostaining of brain sections
Serial 50-70 µm-thick brain sections were obtained with a Vibratome VT1000S
(Leica). For storage, sections were kept in 0.05% sodium azide in PBS at 4◦C. For
immunostainings, sections were first washed in PBS. Then, they were permeabilized
in 0.5% Triton X-100 in PBS for 30min on a shaker. Next, sections were washed in
PBS and blocked for 1.5 h at RT on a shaker. After washing in PBS, sections were
incubated three days in primary antibody solution at 4◦C on a shaker. Next, sections
were washed three times in PBS for 10 min, and incubated overnight at 4◦C on a
shaker in secondary antibody solution. Both primary and secondary antibodies were
usually diluted 1:300. Dapi was used to stain cell nucleus, added to the secondary
antibody solution in 1:2000 dilution from a 1 mg/ml stock. After the secondary
antibody incubation, sections were washed 3 times for 10 min in PBS and mounted
in mowiol mounting medium. Mounted sections were left to dry overnight at RT and
stored at 4◦C for further use.
Antigen retrieval was needed for some antibodies and it was mandatory to detect
myc in brain sections. For that purpose, before the staining protocol, sections were
incubated for 30 min at 95◦C in 10 mM Sodium citrate, 0.05% tween 20 in PBS. After
cooling down, sections were washed in PBS. Permeabilization and further staining
procedure as mentioned above was performed.
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3.2.17 Data presentation and statistical analysis
Images were obtained with a Leica SP8 confocal microscope and processed with the
ImageJ software. Data are presented as mean ± SD and significant levels are indicated
with asterisks, corresponding to ∗ p < 0.05, ∗ ∗ p < 0.01, ∗ ∗ ∗ p < 0.001, ∗ ∗ ∗ ∗ p
< 0.0001. The software GraphPad Prism 6 was used for graphical presentation and
statistical analysis. Adobe Illustrator CS6 was used for figure assembly.

4
Results
4.1 Artificial β-sheet proteins are toxic in primary neurons
We analyzed artificial β-sheet protein aggregation and cytotoxicity in primary neu-
rons. To this aim, we first overexpressed mCherry-tagged β-sheet proteins in primary
cortical neurons by transfection (note that β-sheet proteins were also myc-tagged in
all our experiments throughout this thesis, even if not explicitly mentioned), including
mCherry overexpression as a control. Thereby, we could already detect aggregation
of mCherry-tagged artificial β-sheet proteins one day after transfection (Fig.4.1 A,
B). Moreover, to gain insight into the toxicity effects in a time-dependent manner,
we analyzed neuronal death on day one and day three after transfection (10+1 DIV
and 10+3 DIV). Quantification of cell death via cleaved caspase-3 staining, revealed
that β4mCherry and β23mCherry caused significantly more neuronal death than
overexpression of mCherry, which was not toxic. In addition, neuronal death driven
by β4mCherry and β23mCherry overexpression increased in a time-dependent manner
(Fig.4.1 C, D).
To further characterize cytotoxicity effects caused by artificial β-sheet protein ag-
gregation, we analyzed neuronal morphology in transfected hippocampal neurons. In
these experiments, we chose hippocampal over cortical neurons because of their rather
homogeneous morphology and we quantified neuronal complexity by Sholl analysis.
This software is an ImageJ pluggin that sets concentric circles around the soma and
quantifies the number of intersections to these circles. As depicted in Fig.4.2, hippocam-
pal neurons expressing β4mCherry and β23mCherry were less complex than mCherry
expressing neurons.
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Figure 4.1: β-sheet aggregation and toxicity in transfected neurons. (A) E15.5 cor-
tical neurons transfected with either mCherry, which was diffuse throughout the nucleus and
cytoplasm, β4mCherry or β23mCherry, both of which formed cytoplasmic aggregates (ar-
rows), time point 10+1 DIV. (B) Quantification of transfected neurons with aggregates. N=3
independent experiments, 25-45 cells/condition/experiment, One-way ANOVA + Dunett’s
multiple comparison test. (C) Representative images of an immunostaining against cleaved
Caspase-3, time point 10+3 DIV. Top row depicts the cleaved Caspase-3 channel in positive
(left) and negative (right) neurons. Bottow row depicts the merge of immunostained cleaved
Caspase-3 with mCherry fluorescence and the nuclear marker Dapi (notice the apoptotic
nucleus in the left cells). (D) Quantification of transfected cleaved Caspase-3 positive neu-
rons. N=3 independent experiments, 25-45 cells/condition/experiment, Two-way ANOVA +
Tukey’s multiple comparison test.
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Figure 4.2: Sholl analysis in transfected hippocampal neurons. (A) Images of the mor-
phology of E17.5 transfected primary hippocampal neurons, exemplifying the reduced com-
plexity observed in β-sheet-expressing neurons compared to mCherry positive neurons, time
point 10+2 DIV. (B) Quantification of neuronal morphology by semiautomated Sholl analy-
sis, time point 10+2 DIV. N=3 independent experiments, 10-30 cells/condition/experiment,
Two-way ANOVA + Tukey’s multiple comparison test.
Since at the start of this thesis the effects of β-sheet proteins had been characterized
in Hek293T cells [81], we decided to complement our studies in neurons with further
experiments in Hek293T cells. For this purpose, we generated a β23mCherry inducible
stable cell line by making use of the Tet-ON inducible system. Therefore, upon
addition of Dox to the cell media, β23mCherry expression was induced. With this
new inducible Hek293T line, we detected β23mCherry aggregates as soon as one day
after induction, and observed more aggregates accumulating over time (Fig.4.3 A).
In addition, using the MTT toxicity assay, we quantified cell viability at different
time-points after induction. These assays showed that β23mCherry expression caused
significant reduction in cell viability by three days after induction, compared to
uninduced cells (Fig.4.3 B).
Surprisingly, this decrease in viability that we observed, although significant,
was rather modest in comparison to the reported toxicity effects caused by β23
electroporation in Hek293T cells [81][204]. However, previous studies made use of
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β-sheet constructs without an mCherry tag. Thus we decided to investigate ourselves
the effects of the β-sheet proteins without the mCherry tag, which will be referred to as
untagged proteins for the rest of the thesis (note that they still contained the myc tag) .
Figure 4.3: β23mCherry toxicity in an inducible stable cell line. (A) Images of
Hek293T cells with aggregates (arrows) one and three days after expression induction with
Dox. (B) Quantification of cell viability overtime after expression induction, measured by
MTT assay . Viability values of induced cells were normalized to viability values of uninduced
cells. N=4 independent experiments, One-way ANOVA + Bonferroni multiple comparison
test.
In the following experiments, we studied the effects on viability of untagged β4
and β23 in Hek293T cells and in primary cortical neurons. In Hek293T cells, we
transfected β4, β23, and non-aggregating protein α-S824 as a control. In parallel, we
transfected the mCherry-tagged proteins as well, using mCherry as a control. Three
days after transfection we performed MTT assay to quantify cell viability and detected
no decrease neither in untagged, nor in mCherry-tagged β-sheet expressing Hek293
cells (Fig.4.4 A).
In addition, we quantified untagged β-sheet protein driven cell death in transfected
cortical neurons via cleaved Caspase-3 staining. In these experiments, despite extensive
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protein aggregation, only expression of untagged β4, but not β23, lead to significant
cell death in comparison to the control (Fig.4.4 B). Moreover, β4 induced neuronal
toxicity was lower as compared to β4mCherry driven neuronal death (Fig.4.1 D).
However, we did not quantify and compare the expression levels of the different
β-sheet proteins. Transfection rates in neurons are very low [208], which made β-sheet
detection by western blot impossible in our hands.
At this point, mCherry-tagged β-sheet proteins had shown the most robust toxicity
in transfected neurons in our experiments. Given that we aimed to focus on the
neuronal effects of β-sheet protein aggregation, we proceeded to further confirm the
toxicity of mCherry-tagged proteins in these cells at a population level. For this
purpose, we transduced primary cortical neurons at 10 DIV with lentivirus (LV) and
analyzed cell viability at different time points. Moreover, since we achieved high
transduction rates, we performed western blots to control for protein expression levels.
We observed increasing fluorescence starting from two days after transduction
(10+2 DIV) and β-sheet protein aggregation from 10+4 DIV (Fig.4.5 A). Therefore,
we performed western blots at 10+3 DIV. Furthermore, cell viability was measured
at 10+3, 10+4, 10+6, 10+10, and 10+14 DIV via MTT assay. β4mCherry and
β23mCherry led drastically to neuronal death over time, while mCherry expression did
not impair neuronal survival even fourteen days after transduction (Fig.4.5 B). Notably,
western blot quantification showed no significant expression level differences among
mCherry, β4mCherry, and β23mCherry (Fig.4.5 C, D). Therefore, we confirmed that
mCherry-tagged β-sheet protein expression resulted in neuronal survival impairment
both in transfected and LV-transduced primary neurons.
Overall, we confirmed that artificial proteins β4mCherry and β23mCherry formed
aggregates and lead to neuronal death in a time-dependent manner in primary neurons.
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Figure 4.4: β-sheet toxicity of non-mCherry-tagged constructs. (A) Quantification
of cell viability in transfecetd Hek293T cells measured by MTT assay. N=2 independent
experiments. (B) Quantification of transfected cleaved Caspase-3 positive neurons expressing
either control protein α-S824 or untagged β-sheets. E15.5 cortical neurons. N=3 indepen-
dent experiments, 25-50 cells/condition/experiment, Two-way ANOVA + Tukey’s multiple
comparison test. (C) Images of transfected primary cortical neurons. Cells expressing β4 and
β23 presented multiple aggregates both in the nucleus and cytoplasm.
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Figure 4.5: β-sheet toxicity in transduced neurons. (A) Images of LV-transduced E15.5
cortical neurons with aggregates (insets). (B) Quantification of neuronal viability over time
after transduction. Viability values were normalized to untransduced neurons. N=4 indepen-
dent experiments, Two-way ANOVA + Tukey’s multiple comparison test. (C) Representative
Western blot of neuronal lysates. (D) Western blot quantification showed no difference in ex-
pression between mCherry and β-sheet proteins in transduced neurons, time point 10+3 DIV.
N=4 independent experiments, One-way ANOVA + Tukey’s multiple comparison test.
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4.2 Interactome analysis of β-sheet proteins in primary neu-
rons
Previous studies have shown that several proteins aberrantly interact and coaggre-
gate with naturally aggregating proteins, contributing to their toxicity mechanisms
[125, 118]. Since we aimed to find out which molecular players were involved in
β-sheet-mediated neuronal death in primary cultures, we performed interactome
analysis. Thereby, we focused on the identification of protein candidates which were
potentially involved in common mechanisms of cell toxicity due to protein misfolding.
Figure 4.6: Interactome analysis of β-sheet proteins. Schematic representation of the
process of interactome identification and further candidate validation approaches.
To identify the β-sheet interactomes we transduced E15 primary cortical neurons at
10 DIV (these viruses were kindly provided by Alexandra Lepier from the LMU viral
vector facility). At an early stage of toxicity, 10+4 DIV, we lysed the cells and did an
immunoprecipitation (IP) against mCherry. After further lysate processing, we used
label-free mass spectrometry to identify the interactomes of β4mCherry, β17mCherry
and β23mCherry. As before, we used mCherry expressing neurons as control and for
normalization. Of note, all immunoprecipitations and mass spectometry analyses were
performed by Daniel Hornburg. Figure 4.6 schematically summarizes the procedures
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for interactome identification and further experiments based on the identified protein
interactors.
We identified ninety-eight different proteins which interacted significantly with
the β-sheet proteins in comparison to mCherry. Table 4.1 lists all these interactors,
including the enrichment for each of the β-sheet proteins and the corresponding
p-value. Moreover, the list has been sorted from highest to lowest enrichment for
β23mCherry, and color-coded depicting highest enrichment in green and lowest in red.
Interestingly, we identified several common interactor proteins, as well as proteins
specifically interacting with some of the β-sheet proteins (Fig.4.7 A). In addition,
we analyzed the content of intrinsically disordered regions (IDR) of the significant
interactors versus all proteins detected. IDRs are polypeptide segments having low
aminoacid sequence complexity, that do not fold into a stable tertiary structure, and
often act as critical hubs in protein interaction networks [209]. Proteins with high IDR
content are prone to interaction and coaggregation [210]. Consistently, we detected
an enrichment of low complexity aminoacid sequences in the population of β-sheet
protein interactors (Fig.4.7 B).
Furthermore, gene ontology (GO) annotation [211] of the interactors revealed
that these proteins are involved in a wide variety of cellular functions. Annotation
enrichment classification [212] particularly highlighted their involvement in kinase
signaling, cell morphology, cellular transport, and synaptic transmission (Fig. 4.7 C).
Finally, we also quantified the total proteomes of mCherry and β-sheet protein-
expressing primary neurons. Importantly, we detected that the protein levels of almost
all β-sheet interactors were unchanged in comparison to their expression levels in
mCherry-expressing neurons. Therefore, their interaction with the β-sheet proteins
was not caused by an augmentation in protein availability. Notably, artificial β-sheet
protein expression lead to changes in the expression levels of some proteins, which
we detected to be mostly in response to β23mCherry expression. Most of these
proteins were related to metabolic processes (Table 4.2). Interestingly, we measured a
downregulation of Sorl1 receptor, which has previously been genetically linked to AD
[213, 214]. Moreover, other interesting changes in protein expression which we detected
were the upregulation of the presynaptic protein synaptophysin, and the upregulation
78 4. Results
of Ubl5, a protein linked to extended lifespan in C.elegans [215].
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Table 4.1: Interactome of β-sheet proteins. List of significantly enriched interactors.
Color code ranges from dark red for no enrichment to dark green for highest enrichment. The
cutoff value for enrichment was set at log2≤-1, which equals to at least a two-fold enrichment.
The value for significance was (-log10)≥1.3, which equals to a p value≤0.05.
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Figure 4.7 (previous page): Interactome charachterization. (A) Venn diagram depicting
the number of interactors identified for each β-sheet protein. These interactors were signifi-
cantly enriched in the β-sheet protein samples in comparison to the mCherry samples. N=4
independent experiments. (B) Measurements of low complexity aminoacid sequence content
in β-sheet interactor proteins in comparison to all identified proteins. Two-sample Wilcoxon
test. (C) Annotation enrichment for β-sheet interactors. These annotations represent a com-
bination of gene ontology (GO) [216] and Kyoto Encyclopedia of Genes and Genomes (KEGG)
enrichments [217].
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Table 4.2: Changes in proteome with β-sheet protein overexpression. List of proteins
the expression of which was changed in β-sheet vs mCherry expressing neurons. Color code
ranges from dark red for highest downregulation in expression to dark green for highest
upregulation. The cutoff value for enrichment was set at log2≤ ±1, which equals to at least
a two-fold enrichment. The value for significance was (-log10)≥1.3, which equals to a p
value≤0.05.
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4.3 Artificial β-sheet proteins interact with essential cellular
proteins
Interaction with β-sheet proteins might prevent other proteins from fulfilling their
endogenous functions, perhaps leading to similar loss of function effects as a protein
KO. To investigate this possibility, we selected 19 interactors for further experimental
validation (Table 4.3). Our main candidate selection criteria were: reported links to
neurodegeneration, the candidate’s role in critical pathways for NDs, and their novelty.
We made use of a Crispr/Cas9 screening approach for validation, thereby determin-
ing which candidates were necessary for neuronal survival. To that aim, we transduced
WT primary cortical neurons with lentivirus to coexpress the single guide RNA
(sgRNA) and Cas9 [218]. For each selected candidate, we used three different sgRNAs
for reproducibility and to rule out possible off-target effects. In our initial preliminary
experiments, we transduced at 2 DIV, which caused an unexpected proliferation of
what looked like progenitors from the cortical hem. Therefore, we decided to transduce
at 10 DIV when cells are more mature, by which the proliferation was prevented (data
not shown). Two weeks after transduction with the sgRNA/Cas9 virus, time to enable
protein candidate degradation [219], we analyzed neuronal viability by MTT assay.
We normalized neuronal survival to a negative control condition, in which neurons
were transduced with a LV expressing Cas9 and a sgRNA which did not target any
genomic sequence. In addition, BDNF KO was used as a positive control for neuronal
death in all experiments.
We detected that KO of several candidates led to a significant reduction in neuronal
survival, as shown both in a heat map and a bar graph in Figure 4.8 B, C. The KO of
candidates Ccdc88a, Aimp1, and Stmn2 led to the strongest effect in viability, since
all three guides caused significant neuronal death. Also remarkable were the KOs of
candidates Ap3m1, Hcfc1, Aldh1b, Stmn3, and Clcn3, which also led to significant
reductions in neuronal viability with one or two guides. Overall, these data suggested
that β-sheet proteins interacted with essential cellular proteins, possibly disturbing
their correct function.
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Figure 4.8 (previous page): Knock-out of specific β-sheet protein interactors in cor-
tical neurons. (A) Schematic representation of the used Crispr/Cas9 system. The Cas9
protein, which contains two nuclease domains, introduces double-stranded breaks (DSB), at
sites defined by the sgRNA. Cas9 also requires that a short conserved sequence, known as Pro-
tospacer adjacent motif (PAM), follows immediately 3’ of the target complementary sequence.
DSBs can be repaired by the cellular non-homologous end joining (NHEJ) pathway, resulting
in insertions and/or deletions which disrupt the targeted locus. (B) Heatmaps displaying the
enrichment of selected candidates in the interactome (grey-red) and the cell viability results
in MTT assays after Crisr/Casp9 KO of the candidate (white-blue) in E15.5 cortical neurons.
For the viability results: N=3 independent experiments, Unpaired t-test + Welch’s correc-
tion. ] p-value < 0.05, ]] p-value < 0.01, ]]] p-value < 0.001. (C) Bar graph representation
of the cell viability results in MTT assays after Crisr/Casp9 KO of the candidate. Same data
as white-blue heatmap, with the addition of the BDNF control.
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4.3.1 Ccdc88a (girdin) overexpression does not rescue β-sheet toxicity in
primary neurons
One essential protein interacting with the β-sheet proteins in cortical neurons and
in Hek293T cells [204] was Ccdc88a, also known as girdin. Girdin is an actin-binding
protein which can be phosphorylated by Akt [244], and is ubiquitously expressed
in mammalian cells. Moreover, girdin acts as a guanidine exchange factor (GEF)
and integrates signals from various ligand-activated receptor types, such as receptor
tyrosine kinases and GPCRs [245]. This integrative position involves girdin in a variety
of cellular functions, including: cell migration, survival, autophagy, cell polarity, and
endocytosis [246, 247]. Most interesting, girdin KO mice die at P25, and a homozygous
frameshift mutation in the girdin gene creating a TAG stop codon causes progressive
encephalopathy with odema (PEHO) like syndrome in humans [222]. Thus, we
hypothesized that girdin’s loss of function by its interaction with the β-sheet proteins
might contribute to neuronal cytotoxicity. That being the case, girdin overexpression
could improve neuronal viability.
To test this, we coexpressed a GFP-tagged C-terminal fragment of mouse girdin
(aminoacids 1122 to 1871) with either β4mCherry or β23mCherry using lentivirus.
GFP coexpressed with the β-sheet proteins was used as a control, and we analyzed
neuronal viability by MTT assay 10 and 14 days after transduction. Moreover, we
thought that girdin expression levels could play a role in rescuing toxicity and we
therefore used three different amounts of girdin virus to try to rescue toxicity: 0.25,
0.5, and 1 µl/well. However, girdin overexpression did not rescue neuronal viability in
any condition (Fig.4.9 A).
To test if the use of the C-terminal fragment was not enough to rescue toxicity
because of the lack of girdin’s microtubule binding domain, which is at the N-terminus,
we included a condition in which we coexpressed full-length girdin. However, neither
the fragment nor the full-length protein improved neuronal viability in our experimen-
tal conditions (Fig.4.9 A).
Furthermore, we also checked the expression levels of mCherry, β4mCherry, and
β23mCherry by Western blot. Coexpression of these proteins with GFP resulted in a
slight reduction in their expression. However, coexpression with the highest amount
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of C-terminal fragment girdin resulted in stronger expression reduction (Fig.4.9 B),
especially of mCherry and β4mCherry. Hence the trend towards improved cell viability
observed in the β4mCherry expressing neurons (Fig.4.9 A), was probably due to its
lower expression levels.
A plausible explanation for the downregulation in expression that we detected
might be that both β-sheets and girdin were expressed under the same promoter
(human Synapsin1a promoter), most likely leading to a competition for transcription
factors between the two constructs, and the consequent reductions in expression.
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Figure 4.9: Neuronal death caused by β-sheets is not prevented by Girdin over-
expression. (A) Neuronal viability measured by MTT assay. Neither overexpression of
the C-terminal fragment of girdin (C’), nor the full-length (FL) girdin improved viability in
presence of β4mCherry or β23mCherry. N=4. (B) Representative Western blot image and
quantification of three experiments revealed that coexpression of girdin with mCherry or the
β-sheet proteins resulted in their downregulation, respectively. E15.5 cortical neurons. N=3,
time point 10+4 DIV.
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4.4 Artificial β-sheet proteins might impair survival signaling
In our interactome data set in primary cortical neurons, one prominently enriched
GO term was ”Protein serine/threonine kinase activity” (Fig.4.7 C). Thus, we
hypothesized that one of the mechanisms by which β-sheet proteins cause cytotoxicity
is impairing kinase signaling. Consequently, as a secondary validation approach, we
analyzed kinase-mediated survival signaling in β-sheet protein presence. In particular,
we studied BDNF signaling and focused on Akt and Erk 1/2 phosphorylation as an
indication of neuronal survival signaling activation.
Figure 4.10: Akt signaling is impaired by β-sheet protein expression. (A) Representa-
tive image of a Western blot suggesting less P-Akt in β4mCherry and β23mCherry expressing
neurons. 10+4 DIV LV-transduced E17.5 hippocampal neurons were treated with different
concentrations of recombinant hBDNF for 30min and lysed afterwards. (B), (C), and (D)
Quantifications of Western blot signals using ImageJ. N=3, One-way ANOVA + Tukey’s mul-
tiple comparison test. Significance indicated in (C) refers to the difference in P-Akt levels
among β4mCherry and β23mCherry expressing neurons to the respective counterpart condi-
tion in mCherry expressing neurons.
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Figure 4.11: Erk signaling might not be impaired by β-sheet protein expression.
(A) Image of a Western blot against P-Erk1/2 and Erk1/2. 10+4 DIV LV-transduced E17.5
hippocampal neurons were treated with different concentrations of recombinant hBDNF for
30min and lysed afterwards. (B), (C), and (D) Quantifications of Western blot signals using
ImageJ. N=4, One-way ANOVA did not show any statistical differences.
Our experimental approach consisted of, first, transducing primary hippocampal
neurons at 10 DIV. Four days after transduction, we applied a range of human
BDNF (hBDNF) concentrations to the cells ranging from 0 to 25 ng/ml, for 30min.
Then, we lysed the neurons and performed western blots. We first blotted against
phosphorylated Akt or Erk1/2 (P-Akt, P-Erk1/2), stripped the membranes, and
blotted against the non-phosphorylated proteins for signal normalization. In addition,
as a loading control, we used tubulin.
Interestingly, we observed a trend towards a reduction in the ratio of P-Akt/Akt
in β-sheet protein presence (Fig.4.10 A,B), although it was not significant to mCherry
control. When normalizing P-Akt to Tubulin, the reduction in phosphorylated Akt in
β-sheet protein presence in comparison to mCherry was very prominent. Moreover, we
detected a BDNF dose-dependent effect in the control condition, but not in β-sheet
protein expressing neurons (Fig.4.10 C). Alternatively, no significant differences in Akt
levels were detected (Fig.4.10 D).
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Conversely, no difference neither in P-Erk/Erk, nor in P-Erk levels, was detected
between mCherry and β-sheet protein expressing neurons (Fig.4.11), suggesting a
specific reduction in pro-survival P-Akt, but not P-Erk signaling. Nevertheless, the
results we obtained for Erk signaling were highly variable and further experiments
would be necessary.
Overall, our interactome analysis in primary neurons allowed us to identify both
single proteins and pathways which might be affected in the presence of amyloid-like
aggregating proteins.
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4.5 Novel β23 transgenic mouse model
4.5.1 Broad β23 expression in the forebrain
In order to study gain of function toxicity caused by protein aggregation in vivo,
we generated a novel transgenic mouse model with β23 expression. We generated
a construct which consisted of the myc-tagged β23, separated from mCherry by an
Frt-flanked IRES sequence. Thereby, mycβ23 and mCherry were expressed in the same
cell, but translated separately. Mice in which mycβ23 and mCherry were expressed as
separate proteins will be further referred to as unrecombined. In addition, the presence
of Frt sites gave an additional possibility of excision of the IRES sequence, resulting
in a mycβ23mCherry fusion construct. Therefore, mice in which mycβ23mCherry was
expressed as a fused protein will be further referred to as recombined.
Moreover, the β23 transgene was placed under control of a tetracycline-inducible
promoter (pTRE3G) consisting of 7 repeats of a 19 bp tet operator sequence located
upstream of a minimal CMV promoter (Figure 4.12). This tetracycline inducible
system allowed for temporal controlled β-sheet protein expression. Specifically, we
made use of the Tet-OFF system to control expression: in absence of Doxycycline
(Dox, a derivative of tetracycline which is a preferred effector [248]), the tTa protein
can bind to the promoter and expression is activated. However, in presence of Dox,
tTa cannot bind the promoter and expression is prevented [249]. Another widely used
strategy in mouse genetics is the Tet-ON system, in which the reverse tTa protein
(rtTa) is capable of binding the operator only if bound by a tetracycline [250].
To induce expression in the brain, specifically in the forebrain, we crossed our β23
mice to the broadly used CamkIIα:tTa line [205], whithout administering Dox to the
mice. These mice will be further referred to as CamK;β23. Then we analyzed the
brains of double transgenic mice and controls to identify the expression pattern of
the new mouse line. To that aim, we performed immunostainings a the age of 4.5-5
months. As observed via mCherry staining, expression was as expected restricted to
the forebrain (Fig.4.13 A). Moreover, if we focused on regions which are especially
important in NDs, we observed that in the neocortex mCherry-positive cells were
detectable in all layers. In the hippocampus, we detected expression only in the CA1
(Fig.4.13 A’), but not in CA3 or the dentate gyrus. Moreover, conspicuous mCherry
expression was detected in the striatum (Fig.4.13 A”).
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Subsequently, to make sure that β23 was expressed as well, we coimmunostained for
myc and mCherry. We could clearly identify several mycβ23 positive cells in the neo-
cortex of double transgenic mice. On the contrary, neither myc nor mCherry expression
were detected in single transgenic β23+ mice, demonstrating the absence of leakyness
in expression (Fig.4.13 B). Of note, co-staining revealed many more mCherry-positive
cells than double myc and mCherry-positive cells. In addition, we did not detect clear
myc staining neither in the hippocampus nor in the striatum. Although cells should be
positive for both stainings, these differences in expression patterns may be explained
by differential penetrance of the antibodies, or by non-stoichiometric expression of β23
and mCherry. Finally, due to the CamkIIα-driven expression, we expected expression
of our transgene only in neurons, but not in glia. To analyze if that was the case, we
stained against mCherry and the neuronal marker NeuN. Thereby, we did not detect
any mCherry positive, NeuN negative cell, confirming the solely neuronal expression
(Fig.4.14).
Figure 4.12: β23 expression strategy. Schematics depicting the transgene contained by
the β23 mice. Of note, the Frt DNA sequence is in frame with the rest of the peptide
and translates into the aminoacid sequence highlighted by the dashed lines. To induce β23
expression, mice need to be crossed to tTa mice (CamkIIα:tTa mice in this case). In absence
of Dox, the tTa protein can bind to the TRE promoter and expression is induced, whereas
administering Dox to mice prevents tTa binding and β23 expression is repressed.
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Figure 4.13 (previous page): β23 expression pattern in CamK;β23 unrecombined mice
is restricted to forebrain.(A) Immunostaining showing mCherry expression in the brain
of unrecombined double transgenic mice at 20 weeks of age. (B) Co-staining against myc and
mCherry in the cortex of a double transgenic mouse and a single transgenic β23+ control.
No staining was visible in the control, indicating no leakyness in β23 expression.
Figure 4.14: β23 is expressed only in neurons. Immunostaining depicting colocalization
of mCherry positive cells with neuronal marker NeuN (arrows) in the cortex of a double
transgenic CamK;β23 mouse of 40 weeks of age. Different cortical regions of at least three
mice were visually inspected.
4.6 β23 causes brain atrophy in CamK;β23 mice
Observing the brains of positive double transgenic CamK;β23 mice and their
littermates at macroscopic level, we detected that they differed in size (Fig.4.15
A). We therefore measured the brain weight at different ages. At the early age of
one month, CamK;β23 unrecombined mice had slightly smaller brains than their
littermate controls. Indeed, the difference was significant only between non-transgenic
and double transgenic mice. With increasing age, the differences in brain weight of
double transgenic CamK;β23 mice compared to all other three genotypes became more
pronounced (Fig.4.15 B). Although brains from non-transgenic, β23 single transgenic,
and CamkIIα:tTa single transgenic mice kept on growing with age, that was not the
case for the brains of CamK;β23 unrecombined mice. With regard to the animal’s body
weight, we detected no differences among genotypes at any measured age (Fig.4.15 C).
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Notably, a previous report showed that expression of the tTa protein induced neuro-
toxicity in the granule cell layer of the dentate gyrus in the CamkIIα:tTa model. They
reported that the degree of toxicity varied among several genetic backgrounds and was
strong in mice on at least 50% CBA background. Moreover, while mice on C57BL/6
background were protected, they performed poorly in memory tests [251]. For our
experiments, we purchased the CamkIIα:tTa mouse line from the Jackson laboratory
on 50% CBA, 50% C57BL/6 background and kept it on this background. Since our
β23 line was pure C57BL/6, offspring from crossing the two lines were 25% CBA,
75% C57BL/6. By lowering the CBA background without removing it completely, we
aimed at circumventing both the toxicity and the poor behavior performance. Never-
theless, our brain weight data indicated that tTa single transgenic mice might not be
completely free of tTa-induced neurotoxicity because their brain weights were slightly
lower when compared to non-transgenic and β23 single transgenic controls (Fig.4.15 B).
Besides measuring brain weight, we quantified the cortex width of double transgenic
CamK;β23 mice at five months of age. We compared it to the cortex width of tTa
single transgenic mice and found that double transgenic mice had a significantly
thinner cortex (Fig. 4.15 D, E).
Moreover, the paper mentioned above reported that Dox treatment during de-
velopment of the mice, would prevent dentate gyrus degeneration [251]. Therefore,
we administered Dox in sucrose water (2mg/ml Dox concentration) to mice from E0
until weaning for testing. Then, we measured the brain weight of these mice at 20
weeks and 95-105 weeks of age (22-24 months). In agreement with literature, our
brain-weight data indicated that Dox treatment prevented the reduction in brain
weight in single-transgenic tTa mice. However, we also detected no decrease in brain
weight in CamK;β23 expressing mice (Fig.4.15 F), suggesting that β23 does not
cause gross morphological defects when its expression under the CamkIIα promoter
is restricted to post-developmental age. Possibly, these results might be attributed
to constantly lower expression levels after Dox treatment, since we observed that
mCherry fluorescence was not as strong in Dox treated brains as compared to brains
of non-Dox mice. Altogether, these results suggest that β23 expression could lead
to brain atrophy in an age-dependent manner and in an expression level-dependent
manner, although β23 may exert strongest effects during embryonic development.
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Figure 4.15 (previous page): CamK;β23 unrecombined mice present brain atrophy.
(A) Images of perfused brains of a non-transgenic control mouse and littermate double trans-
genic CamK;β23 mouse, both females of 20 weeks of age. Dashed lines outline the forebrains
of the non-transgenic brain (white) and the double transgenic brain (blue). (B) Quantification
of brain weight at different ages. All female mice. Numbers on the bars indicate the number
of animals. Statistics: Two-way ANOVA + Tukey’s post-test. (C) Body weight quantifica-
tion of the same mice as in B. (D) Image depicting the difference in cortex width. Cux1 was
used as upper cortical layer marker and Foxp2 as a marker for lower cortical layers. Foxp2
staining suggests a reduction in lower layer width, which may be due to reduced neuronal
numbers. (E) Cortex width measurements in two brain sections. Measurements of the motor
cortex were performed. All female mice of 22 weeks of age. (F) Brain weight quantification
of unrecombined mice that received Dox from E0 to P21. Both female and male mice pooled
together.
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4.7 CamK;β23mCherry recombined mice do not show brain
atrophy
By crossing our β23 mouse line to a flippase mouse line, we induced recombination
of the frt sites in the construct, and the IRES was excised. Thereby, β23 and mCherry
were expressed as a fusion protein after crossing this recombined line to CamkIIα:tTa
(Fig.4.16 A). Indeed, when we did an immunoprecipitation (IP) against mCherry, using
forebrain lysate, and blotted against myc, we detected one clear band at approximately
37kDa, the size of the fusion protein (Fig.4.16 B). These results were confirmed by
blotting against mCherry. On the other hand, unrecombined β23 would have run at
10kDa [81], which we did not detect. Moreover, we did not detect any signal in single
transgenic mice, further indicating that our line is not leaky, as shown above in Figure
4.13 B.
Immunostaining against mCherry revealed β23mCherry expression restricted to the
forebrain (Fig.4.16 C), as observed in the unrecombined line. Although the restricted
expression pattern given by CamkIIα:tTa-driven expression was conserved, we did not
detect β23mCherry in the CA1 region of the hippocampus in the recombined line. In
addition, comparison of cortical expression between unrecombined and recombined
mice, showed strong β23mCherry expression in neural processes, while mCherry
is stronger in the soma in the unrecombined mouse (Figure 4.16 D). Furthermore,
β23mCherry aggregates were readily detected in the recombined line and β23mCherry
localized also throughout the cell soma (Fig.4.16 E). Finally, we measured the brain
weight of recombined mice at 40-42 weeks of age and compared the results to the brain
weight of unrecombined mice. Surprisingly, recombined mice did not present brain
atrophy (Fig.4.16 F), suggesting that β23 and β23mCherry lead to different effects in
brain architecture.
Overall, we detected the progressive effect on brain atrophy only in CamK;β23
unrecombined, non-Dox treated mice (Fig. 4.15 B). Based on these results, we
decided to focus on these mice for further histological and behavioral characterization.
Therefore, following findings are from experiments with mice which did not receive
Dox during development, and expressed β23 and mCherry as two separate proteins.
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Figure 4.16 (previous page): Recombined β23mCherry expression does not lead to
brain atrophy. (A) Schematic of the transgene expressed by CamK;β23 recombined mice.
The IRES sequence was excised out by flippase recombination and mice express the fused
β23mCherry protein. (B) Western blot after immunoprecipitation against mCherry in fore-
brain lysates. Only double transgenic mice express β23mCherry. Last two columns are
control lysates from Hek293T cells transfected with either β23mCherry or mCherry. Note
that β23mCherry runs slightly higher in the brain lysate than in the cell lysate, probably
because of the remaining of one frt sequence in the construct after recombination. (C) Ex-
pression pattern of β23mCherry in the forebrain, shown by mCherry staining at 20 weeks
of age. (D) Comparison of mCherry staining in the cortex of CamK;β23 unrecombined and
recombined mice, both females of 20 weeks of age. (E) Higher magnification images revealing
β23mCherry aggregates in cortical neurons of a CamK;β23 recombined mouse. (F) Brain
weight quantification demonstrating no brain weight reduction in recombined mice, in com-
parison to unrecombined. The data for the unrecombined mice is the same as shown in Fig.
4.15 B. Only female mice used for unrecombined measurements and both female and male
used for the recombined. Statistics: One-way ANOVA + Tukey’s multiple comparison test.
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4.8 β23 may impair nucleocytoplasmic transport in vivo
It has been previously reported that artificial β-sheet proteins impair nucleocyto-
plasmic transport of proteins and mRNA in Hek293T cells [204]. Interestingly, in our
CamK;β23 mouse model, we detected that β23 localized to the nuclear membrane of
cortical neurons (Fig.4.17 A, B). Moreover, β23 aggregates accumulated also along
neurites (Fig.4.17 C). Interestingly, the nuclear membrane localization of β23 in
neurons had not been reported before and the presence of small β23 accumulations in
the nuclear membrane suggested a possible interference with the nucleocytoplasmic
transport in vivo.
Several nuclear pore proteins (Nups) and transport factors have been reported to
mislocalize and coaggregate with aggregating proteins such as Huntingtin, TDP-43,
and DPRs [135, 134, 137, 130]. Moreover, abnormal localization of Ran GTPase-
activating protein 1 (RanGAP1) is recurrent among different diseases. Accordingly, we
detected partial colocalization of RanGAP1 with β23 in double transgenic CamK;β23
unrecombined mice (Fig.4.18). In addition, immunostaining against one of the Nups
located in the nuclear pore basket, Nup153, showed partial colocalization with β23, as
well as sporadic mislocalization of Nup153 to the cytoplasm (Fig.4.19). These qualita-
tive data suggest that β23 might be neurotoxic in vivo by hindering nucleocytoplasmic
transport. However, experiments to assess transport functionality would be necessary
to confirm this hypothesis, and the performance of such experiments would not be
trivial in vivo.
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Figure 4.17: β23 forms inclusions at the nuclear membrane and in neurites. (A
and B) High magnification confocal images, exemplifying neurons in the cortex with β23
inclusions around the nuclear membrane. (C) Low magnification example of a cortical neuron
with inclusions around the nuclear membrane and along the neurites (arrow). All images from
layers III to VI of the cortex of a 20-week-old, CamK;β23 unrecombined mouse.
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Figure 4.18: Partial colocalization of β23 inclusions with RanGap1. Confocal image
of a brain section stained against myc and RanGap1, illustrating partial colocalization of β23
with RanGap1. Cortex layers II-III of a 20-week-old, CamK;β23 unrecombined mouse.
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Figure 4.19: Partial colocalization of β23 inclusions with Nup153. (A and B) Confocal
images of two example neurons with Nup153 mislocalization to β23 aggregates. (C) Example
image of a β23 negative neuron showing Nup153 staining only around the nucleus. All images
taken from the layer VI of the cortex of a 20-week-old, CamK;β23 unrecombined mouse.
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Thus, in order to study nucleocytoplasmic transport functionality in presence of
β23 in a simpler system, we have generated a lentiviral construct which is analogous
to the mouse construct (Fig.4.20 A). Expression of this construct resulted in aggregate
formation and neuronal death in primary cortical neurons (Fig. 4.20 B, C), and could
be a valuable tool for further mechanistic experiments.
Figure 4.20: Lentivirus to study β23 effects on nucleocytoplasmic transport in
vitro. (A) LV-construct to study NCT in cultured neurons. The mouse pTRE3G promoter
was exchanged for a neuronal-specific hSynapsin1 promoter. (B) Single confocal plane image
depicting expression of the LV-construct in primary cortical neurons. Early β23 aggregation
was detected at 10+4 DIV and abundant aggregation at 10+14 DIV. (C) Quantification of
toxicity induced by expression of the construct in E15.5 primary cortical neurons. Viability
measured by MTT assay. N=5, Unpaired t-test + Welch’s correction.
Of note, we observed that mCherry formed inclusions both in vitro and in vivo
(Fig.4.17 A, Fig.4.20 B). Nevertheless, when expressing the mouse construct in vitro,
we detected β23 aggregation prior to mCherry aggregation (Fig.4.20 B, upper row).
These results suggest that mCherry aggregation was not the driving force for β23
aggregation, but β23 accumulation probably enhanced mCherry aggregation.
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4.9 CamK;β23 unrecombined mice present no deficits in be-
havioral tests
To investigate if artificial aggregating protein β23 expression in the forebrain of
CamK;β23 unrecombined mice could lead to behavioral effects, we performed a panel
of motor and cognitive tests. These tests were performed in collaboration with the
German mouse clinic at the Helmholtz Center in Munich. Analyses were done at a
range of 20 to 43 weeks of age in single-transgenic control animals with either β23+
or tTa+ genotype, and double transgenic tTa+ β23+ mice. Both males and females
were tested in all tests.
The group of motor tests included open field, grip strength, rotarod, beam walk,
and beam ladder analysis. We detected no significant differences among genotypes
in the total traveled distance, the total number of rears, and the time spent in the
center measured in the open field test (Fig.4.21 A-C). Moreover, although there was a
trend towards reduced fore- and hindlimb strength in female double transgenic mice,
there were no significant differences among genotypes in limb strength measured in the
grip strength test (Fig.4.21 D, E). Furthermore, no impairment in motor coordination
and balance was detected in the accelerating rotarod test (Fig.4.21 F). Finally, we
assessed fine motor movement with the beam and ladder walk tests. These analyses
showed that tTa+ and tTa+ β23+ animals needed more time to traverse the beam
and ladder, and stopped more times in comparison to β23+ mice. However, double
transgenic performance was not different from that of tTa+ control mice (Fig.4.22
A-D). In summary, we detected no impairment in motor behavior in CamK;β23 mice
at analyzed ages.
Moreover, we performed Y-maze, social discrimination, novel object recognition,
and Intellicage experiments to study memory capacity of our mice. In Y-maze exper-
iments there was no difference among genotypes neither in spontaneous alternation
among arms, nor in the percentage of alternate arm returns. tTa+ β23+ showed a
significant reduction in the number of arm entries in comparison to β23+ animals,
although the difference to tTa+ mice was not significant (Fig.4.23 A-C). In addition,
we detected no difference among genotypes in the social discrimination test (Fig.4.23
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D). In the novel object recognition test, double transgenic animals showed a trend
towards a reduction in recognition of the novel object after a retention interval of 3h
(Fig.4.23 E), whereas the trend was reverted after a retention interval of 24h (Fig.4.23
F). Finally, tTa+ β23+ mice took slightly longer to learn in the place learning test of
the Intellicage. However, in the reversal learning, double transgenic mice performed at
the same level as β23+ mice, and these two genotypes performed significantly better
than tTa+ mice (Fig.4.23 G). In summary, we did not detect any consistent effects in
memory in CamK;β23 unrecombined mice. In fact, results overall suggested that there
might be slight effects on behavior driven by tTa expression, since double transgenic
tTa+ β23+ and single transgenic tTa+ results consistently pointed towards the same
direction, while these results were partially different than the results in β23+ single
transgenic mice.
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Figure 4.21: β23 aggregation does not result in impaired motor behavior in
CamK;β23 unrecombined mice. (A-C) Open field results. Test performed at 22 weeks
of age. (D and E) Grip strength results. Test performed at 31 weeks of age. (F) Rotarod
results. Test performed at 31 weeks of age.
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Figure 4.22: β23 aggregation does not impair fine motor behavior in mice. (A-D)
Pooled results of the beam ladder and balance beam. Tests performed at 33 weeks of age. In
(A) β23+ vs β23+tTa+ are significantly different by Fisher’s Exact test, P = 0.004. In (B)
β23+ vs β23+tTa+ are significantly different P < 0.001.
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Figure 4.23 (previous page): β23 aggregation does not result in impaired memory
test performance in CamK;β23 unrecombined mice. (A, B and C) Y-maze results.
Test performed at 23 weeks of age. (D) Social discrimination results. Test performed at 34
weeks of age. (E and F) Novel object recognition results. Test performed at 36 weeks of age.
(G) Intellicage results. Tests performed at 43 weeks of age.
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4.10 β23 expression in the whole CNS is lethal in NEFH;β23
unrecombined mice
In some NDs, such as ALS and SCA, forebrain structures are not the main affected
regions in disease, but the spinal cord and the cerebellum. In order to study gain of
function toxicity caused by protein aggregation at whole CNS level, we crossed our β23
mice to a different line in which tTa expression is driven by the neurofilament heavy
chain (NEFH) promoter [252]. This mice will be further referred to as NEFH;β23.
Importantly, all work on NEFH;β23 mice was performed with Miguel da Silva Padilha.
Strikingly, genotyping results of four different litters of 3-week-old unrecombined
mice revealed the absence of double transgenic NEFH;β23 animals. We therefore
hypothesized that NEFH;β23 mice might die before reaching this age. Interestingly,
genotyping of two E15 litters revealed the presence of two normally looking and alive,
double transgenic mice. Moreover, we analyzed two more litters at P0 and found that
all NEFH;β23 double transgenic mice were dead, while all other littermates were alive
(Table 4.4).
To test if β23 expression might be related to the lethality phenotype, we con-
firmed β23 expression during development by immunostaining against myc in brain
sections of E18 mice (Fig.4.24 A). Moreover, we administered Dox to NEFH;β23 mice
from conception until P21 to prevent β-sheet protein expression. As expected, Dox-
treated double transgenic NEFH;β23 unrecombined mice were viable (data not shown).
Overall, these results suggested that β23 expression in whole CNS exerted strong
cytotoxicity effects that impaired viability, leading to the animal’s death before or
shortly after birth. This lethality phenotype could be prevented by β23 expression
inhibition via Dox administration (schematically depicted in Fig.4.24 B). Further
experiments on Dox-treated NEFH;β23 mice will be necessary to assess the effects
of β-sheet protein expression throughout the CNS in adult mice at mechanistic and
behavioral levels.
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Analyzed NEFH;β23 unrecombined mice
Embryonic day 15 (E15)
Genotype ] of mice Mendelian ratio
Non-transgenic 1 6%
NEFH:tTa- β23+ 3 18%
NEFH:tTa+ β23- 11 65%
NEFH:tTa+ β23+ 2 11%
Postnatal day 0 (P0)
Genotype ] of mice Mendelian ratio
Non-transgenic 3 25%
NEFH:tTa- β23+ 3 25%
NEFH:tTa+ β23- 3 25%
NEFH:tTa+ β23+ 3 (non-viable) 25%
3 weeks old
Genotype ] of mice Mendelian ratio
Non-transgenic 16 62%
NEFH:tTa- β23+ 7 27%
NEFH:tTa+ β23- 3 11%
NEFH:tTa+ β23+ 0 0%
Table 4.4: Numbers and ages of analyzed NEFH;β23 unrecombined mice
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Figure 4.24: NEFH-driven β23 expression is strong during development and im-
pairs mice viability. (A) Immunostaining confirming β23 expression in E18 NEFH;β23
unrecombined and non-Dox treated mice. (B) Schematics depicting the lack in viability in
NEFH;β23 mice, which can be prevented by Dox-administration during development.
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Discussion
5.1 Effects of synthetic β-sheet proteins in vitro
In this thesis, we characterized the gain of function effects of amyloid-like protein
aggregation on neuronal viability by overexpressing artificial β-sheet proteins. These
proteins had been previously introduced as a model for protein misfolding and aggrega-
tion in a purely in vitro system [203]. Moreover, Olzscha et al. first characterized their
effects on cellular well-being in the Hek293T cell line [81]. However, characterization
of artificial β-sheet protein effects in neurons, the cells which are most vulnerable to
death in NDs, was missing. Therefore, we aimed to address this issue.
5.1.1 Studying the effects of mCherry-tagged synthetic β-sheet proteins:
aggregation
We used myc and mCherry-tagged β-sheet proteins for most experiments, and
focused on β4 and β23, while previous studies used myc tagged proteins without
mCherry. By adding the mCherry tag, we facilitated detection of protein expression
by fluorescence. However, we introduced a possible modifier of protein aggregation,
since mCherry is almost three times bigger than the β-sheet proteins (28 vs 10 kDa).
Thus, aggregation of mCherry-tagged β-sheet proteins needed to be assessed. In
fact, preliminary experiments performed by Dr. Irina Dudanova prior to my thesis,
compared β23 and β23mCherry aggregate load and toxicity in Hek293T cells, show-
ing no large differences between the two constructs (data not shown). These results
encouraged us to continue working with mCherry-tagged constructs in primary neurons.
In agreement with the above mentioned data in Hek293T cells, β4mCherry and
β23mCherry formed aggregates in primary cortical neurons when overexpressed both
by transfection (Fig. 4.1 A, B) or lentiviral transduction (Fig. 4.5 A). In transfected
neurons, aggregates were abundant already after one day, while in transduced neurons
only a few neurons contained aggregates after four days. This time shift could be
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explained by two reasons: the first was the delayed expression in transduced neurons,
in which β-sheet expression started to be detectable by fluorescence two days after
LV-transduction; the second was the differential expression levels, which at the level
of individual neurons were probably higher in transfected neurons than in transduced.
Comparison of expression levels obtained by the two different overexpression methods
is however challenging, since transfection in neurons usually leads to only 1-30% of
transfected neurons [208], which greatly complicates the assessment of protein expres-
sion by, for example, Western blot. In addition, quantification via immunofluorescence
would not be accurate, since aggregates are formed by protein accumulation and are
brighter than the diffused protein.
The number of aggregate-bearing neurons was significantly higher in cells overex-
pressing β4mCherry or β23mCherry, in comparison to control mCherry-overexpressing
neurons (Fig. 4.1 B). Nonetheless, it is important to remark that we also detected
mCherry forming inclusions in control cells. On the other hand, expression in primary
neurons of β23-IRES-mCherry, which leads to β23 and mCherry translation as two
separate proteins, suggested that β23 aggregates could be detected earlier than
mCherry inclusions, indicating that β23 aggregation was not driven by mCherry (Fig.
4.20 A). mCherry is widely used as a fluorescent tag, it is reported to be monomeric
and it is a good compromise between brightness, photostability, and cytotoxicity [253];
nevertheless, alternative fluorescent protein tags such as mScarlet [254] or the widely
used eGFP, may be better options for future experiments with aggregating proteins.
5.1.2 Studying the effects of mCherry-tagged synthetic β-sheet proteins:
neuronal morphology and apoptosis
We have quantified cellular viability in transfected and LV-transduced primary cor-
tical neurons, providing compelling evidence of β4mCherry and β23mCherry-induced
cytotoxicity in neurons. First, quantification of neuronal apoptosis in transfected neu-
rons demonstrated a significant increase in neuronal apoptosis induced by β4mCherry
and β23mCherry expression (Fig. 4.1 D). Moreover, considering that naturally aggre-
gating proteins can interfere with neuronal cytoskeleton and morphology maintenance
[255], we investigated the effects of the β-sheet proteins on neuronal morphology
in transfected hippocampal neurons by Sholl analysis. Similarly, as observed for
poly-GA dipeptide repeat aggregates [118], β4mCherry and β23mCherry expression
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reduced dendritic arborization (Fig. 4.2). Importantly, impaired neuronal morphol-
ogy can have dramatic effects on cellular trafficking, affecting cellular processes,
such as the maintenance of mitochondrial homeostasis, synaptic morphology, and
autophagy-lysosome pathways, which are shared pathological mechanisms in NDs [111].
In addition, we further confirmed the cytotoxic effects of β4mCherry and
β23mCherry aggregation, at a population level and in a time-dependent manner, in
LV-transduced primary cortical neurons. These experiments revealed the progressive
character of β-sheet-induced toxicity, since we measured no effect on neuronal viability
three days after transduction, but the viability of β-sheet-expressing neurons started
decreasing at four days after transduction. According to the characteristic progressive
pathogenesis observed in NDs, cultured β-sheet-expressing neurons continued dying
over time, so that only around 10% of neurons were alive on day fourteen after
transduction. While β-sheet expression strongly affected neuronal viability, control
mCherry-expressing neurons survived as well as untransduced neurons (Fig. 4.5 B),
reinforcing that the observed effects are not driven by mCherry expression.
Unexpectedly, all our viability experiments indicated that β4mCherry-induced
toxicity occurs faster than β23mCherry-induced toxicity, and these results, at least
for LV-transduced neurons, were not a result of differential protein expression levels
(Fig. 4.5 D). These toxicity results were in disagreement with a previous publication,
which reported that β23 was more toxic than β4 [81]. However, in contrast to our
experimental settings, these experiments were performed in Hek293T cells transiently
transfected via electroporation.
Therefore, to find out more about this disagreement in the toxicity results, we
performed viability analysis in transfected Hek293T cells, comparing the effects on
viability exerted by untagged and mCherry-tagged β-sheet proteins. To our surprise,
we were not only unable to reproduce the strong reported toxicity measured in
Hek293T cells expressing untagged β-sheet proteins, but we did not detect any
impairment in viability in Hek293T cells expressing mCherry-tagged proteins (Fig.
4.4 A). Furthermore, as an alternative approach, we also measured cellular viability in
a newly generated, inducible Hek293T cell line, which stably expressed β23mCherry
upon Dox addition to the media. In the viability experiments performed with the
inducible cell line, we detected a mild decrease of around 20-25% in cellular viability
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at time-point four days after expression induction (Fig.4.3 B). Nonetheless, this result
was also distincly lower than the 60% cell death at three days after transfection
reported in Hek293T cells expressing β23 [81, 204]. These discrepancies may however
be due to technical reasons.
Finally, we analyzed the cytotoxicity of untagged β-sheet proteins in transfected
primary cortical neurons. In accordance to the results with the mCherry-tagged
proteins in neurons, untagged β4 was more toxic than β23, although the number of
apoptotic neurons was much lower than in β4mCherry transfected neurons (Fig. 4.4
B). Altogether, the robust cell death observed in neurons versus Hek293T cells indicate
the existence of neuronal specific toxic mechanisms induced by amyloid-like protein
aggregation. Indeed, it is thought that the postmitotic nature of neurons renders them
particularly vulnerable to accumulation of disease-related proteins in NDs [110]. Our
results therefore, point out the importance of validating results in disease-relevant cell
lines. Moreover, our cytotoxicity results suggest that expression levels might play an
important role in the degree of cellular apoptosis induced by artificial aggregating
proteins. This importance of expression levels is reminiscent of the effects elicited by
increased amounts of Aβ and α-synuclein, given that duplications in the Aβ coding
gene APP lead to familial AD [20], and SNCA duplications or triplications lead to
familial PD [29].
At this point, further experiments would be needed to discern the cause of the
differential cytotoxicity detected between untagged and mCherry-tagged β-sheet
proteins in neurons. To test if differences in expression levels were the reason,
transduction of all proteins and comparison of protein levels for example via Western
Blot, along with analysis of population viability could be performed. Alternatively,
differences in toxicity may have been caused by different protein localization of
untagged and mCherry-tagged proteins, since untagged β-sheets form abundant
aggregates in the nucleus, while mCherry-tagged β-sheets primarily localize to the
cytoplasm. In support of this, a study concluded that cytoplasmic localization of
the artificial β-sheet proteins leads to higher cytotoxicity than nuclear localization [204].
In addition, further experiments would be needed to find out more about the tem-
poral difference in toxicity elicited by β4mCherry and β23mCherry. Possibly, in-depth
biophysical characterization of the structure and dynamics of the aggregates would be
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necessary. Given that in vitro data indicate that β4 is less prone to aggregation than
β23 [81], it is reasonable to speculate that β4 may form more oligomeric species, which
could also influence the dynamics of secondary nucleation processes [9]. On the other
hand, the sequences of the two artificial proteins are slightly different, and this could
also have an influence on their aggregation dynamics and the types of interactions
they have with other cellular molecules.
Overall, we have shown that artificial aggregating proteins β4mCherry and
β23mCherry form aggregates, lead to neuronal death in a time-dependent manner,
and can thus be employed to study toxic mechanisms induced by amyloid-like protein
aggregation.
5.2 Identification of molecular candidates with a potential role
in common mechanisms of cell toxicity
5.2.1 Neuronal interactome of β-sheet proteins: comparison to other pro-
teomic studies
Aiming to find out more about the molecular underpinnings involved in β-sheet-
induced toxicity, we performed interactome mass spectrometry analysis. This approach
has successfully been used to identify different molecules and pathways affected by
aberrant interactions of cellular components with naturally aggregating proteins (see
section 2.2.1) and artificial aggregating proteins [81, 204]. Moreover, omics studies are
of growing interest for the neurodegeneration community, due to their great value in
the systematical and comprehensive understanding of phenotypes related to disease [80].
Importantly, our experimental approach aimed at identifying proteins involved
in early stages of toxicity, interactors of predominantly soluble oligomeric β-sheet
species. In addition, although the interactomes of β4, β17, and β23 had been
analyzed in a previous report [81], this previous study was performed in Hek293T
cells and results on β-sheet-induced toxicity in these cells are conflicting (see section
5.1.2). Conversely, our experiments were performed in primary neurons and enabled
us to identify neuronal-specific protein interactors, a factor that is of disadvantage
in cell lines. In addition, a second published study measured the interactome of
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β17GFP in primary cortical neurons, using GFP as a control [204]. While this study
identified several interesting candidates in neurons, the experiments were performed
in transfected neurons and the number of β17GFP-positive cells was probably low.
Moreover, the article did not report neither the time point after transfection in which
experiments were performed, nor the neuronal toxicity at that time point. In contrast,
our LV-transduction approach allowed a broad neuronal-specific population expression,
at an early time point of toxicity (Fig.4.5 B).
We identified close to hundred specific β-sheet interactors with a wide variety of
cellular functions (Fig. 4.7 A, Table 4.1). Importantly, expression of these interactors
was not altered in β-sheet-expressing neurons (Table 4.2), excluding the possibility
that interaction was due to higher protein concentration in the cell. Moreover, in line
with proteins that were sequestered by HTT aggregates in the R6/2 mouse model
[125], the content of intrinsically disordered regions was higher in β-sheet interacting
proteins than in the rest of identified proteins (Fig.4.7 B). This commonality in protein
features brings to mind the concept of a metastable fraction of the cellular proteome
being particularly vulnerable to protein misfolding [256].
In addition, annotation enrichment of the β-sheet interactors highlighted terms
such as transport, microtubule, and cell membrane; suggesting that proteins involved
in aberrant interactions with the aggregating proteins, might have a role in the
observed impairment of neuronal morphology caused by β4mCherry and β23mCherry
(Fig.4.2).
In contrast to the reported interactome in transfected neurons [204], we did not
identify any member of the THOC complex enriched as significant β-sheet interactor.
This difference might be explained by the different experimental conditions used in the
two studies: transfected vs transduced neurons, GFP vs mCherry tag. Furthermore,
transfection leads to very high protein expression levels and it is reasonable to think
that this might influence outcoming results.
5.2.2 Investigation of individual protein candidates
In order to mimic the loss of function effect that aberrant protein interaction
with β-sheet aggregating proteins might have on neuronal viability, we performed a
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Crispr/Cas9 knock-out screen of a subset of interactors. To do so, we selected nineteen
proteins among all the interactors. This selection was based on literature and according
to the criteria determined by the members of the project (Table 4.3). LV-transduction
of the Crispr/Cas9 construct in WT primary cortical neurons, followed by viability
measurements, revealed that KO of individual interactor proteins significantly reduced
neuronal survival (Fig.4.8 B, C).
Particularly, KO of the candidates Ccdc88a, Aimp1, and Stmn2 showed the most
consistent results, since neuronal survival was significantly reduced by the protein
KO with all three different gRNAs. Interestingly, Aimp1 has been linked to AD and
motor neuron degeneration [123, 223], and Stmn2 downregulation was detected in AD
patients [230], confirming that we were able to identify disease relevant candidates
using the artificial β-sheet aggregating proteins.
Nonetheless, further validation experiments would be needed to complement our
screening results, since they are probably an underestimation of the possible effects
given that factors like transduction efficiency of each LV and different protein half-lives
have not been considered in the experiments. As a consequence, it remains an open
question, if the lack of effect in the KO of some candidates was due to low transduction
efficiency, very long half-life of the protein, non-functional KO, or if the protein is
actually not essential for neuronal survival. Especially important, would be to measure
the degree of candidate protein reduction, since we cannot rule out the possibility
that we induced a knock-down rather than a knock-out, as a result of achieving
transduction in only a fraction of cultured neurons.
Finally, we investigated if overexpression of the candidate Ccdc88a (Girdin) in
β-sheet-expressing neurons could rescue neuronal viability. However, girdin overex-
pression did not improve neuronal viability even at the latest analyzed time point,
fourteen days after cotransduction (Fig. 4.9). This result may be explained by girdin
levels not being sufficient to counteract the β-sheet effects, but technical difficulties
hindered us from further investigation. In our experiments, both β-sheets and girdin
constructs were expressed in the same backbone vector and therefore under the same
promoter. Thereby, cotransduction of the two vectors might have lead to competition
for transcription factors and increasing girdin levels resulted in reduced β-sheet protein
levels. Therefore, we were not able to discern between effects on neuronal survival
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elicited by girdin or by reduction in β-sheet expression.
Alternatively, maybe girdin overexpression alone was not enough to rescue viability
and a combination of several proteins, perhaps involved in various cellular pathways,
may be necessary. This option seems reasonable considering the multifactorial patho-
genesis described in NDs [111].
5.2.3 Investigation of pathway impairments
Enrichment of the annotation Protein serine/threonine kinase activity in β-sheet
interactors (Fig. 4.7 C) lead the focus of our attention to neurotrophic signaling,
given that its dysregulation is a commonality in NDs (see section 2.2.3). Therefore,
we became interested in studying the effects of amyloid-like aggregation on trophic
signaling using the artificial β-sheet proteins. As a starting point, we focused on
BDNF-TrkB signaling, which has been widely investigated in earlier years of our
laboratory.
Usually, binding of neurotrophin BDNF to its receptor TrkB, leads to activation
of downstream pathways through three principal tyrosine kinase-mediated pathways:
the MAPK–ERK pathway, the PI3K–AKT pathway and the PLCγ1–PKC pathway.
In our experiments, we studied the first two pathways, which promote cell survival,
whereas the PLCγ1–PKC pathway promotes cell differentiation [139]. Interestingly,
we detected impaired Akt phosphorylation in β-sheet expressing neurons (Fig. 4.10),
suggesting that β-sheet expression hinders the activation of the survival pathway.
Moreover, we detected no difference in Erk1/2 phosphorylation (Fig. 4.11), hinting
at a specific dysfunction of the Akt arm of the survival pathways. However, the
variability among these experiments was very high and further confirmation would be
needed.
Notably, reduced Akt phosphorylative activity caused by its own reduced phos-
phorylation, may explain why girdin overexpression would not be enough to rescue
β-sheet protein toxicity. Girdin gets phosphorylated by Akt [244]. Therefore, girdin
overexpression, without solving the upstream problem in Akt, may not be sufficient to
improve cell viability.
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Our Akt results unraveled another common effect elicited by gain of function in
protein aggregation: the impairment of neurotrophic signaling cascades. However,
many questions remain open: in β-sheet presence, are the levels of receptor TrkB and
P-TrkB maintained? Is the downregulation of P-Akt caused by higher expression of
the upstream kinase PTEN? What are the downstream effects of this downregulation?
What happens to signaling via the other neurotrophin receptors? Does β-sheet
expression in vivo impair neurotrophic signaling as well? Further experiments will
help unravel some of the answers.
In summary, as observed for naturally aggregating proteins [142], artificial β-sheet
proteins might impair neurotrophic signaling in neurons. This shared feature may
enable the testing of small molecules in artificial β-sheet expressing neurons as a
further validation of therapeutic potential in preclinical studies.
5.2.4 Artificial β-sheets proteins in vitro: concluding remarks and outlook
We have assessed the effects of mCherry-tagged artificial β-sheet proteins on
neuronal viability. First, we have shown that β4mCherry and β23mCherry form
aggregates in primary murine neurons. Moreover, our results revealed that β4mCherry
and β23mCherry expression leads to impaired neuronal morphology and to progressive
neuronal death in primary neurons. Thus validating the use of artificial amyloid-
like proteins to study gain of function toxic mechanisms induced by protein aggregation.
In addition, by analyzing the interactome of the artificial β-sheet proteins in
neurons, we have provided a list of protein candidates, which may have a role in
common mechanisms driving neurodegeneration.
At a mechanistic level, we could pinpoint the impairment of neurotophic survival
signaling as one of the possible causes of β-sheet induced toxicity. Overall, the results
reinforce the utility of artificial proteins to mimic and study phenotypes caused by
naturally aggregating proteins.
However, there are still further characterization experiments and open questions
that one might address. To start with, several protein aggregates are ubiquitinated or
tagged by p62 [46, 49]. Checking these features, as well as determining the degradation
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pathway of artificial β-sheet proteins, would serve as their further validation as a
model to study neurodegeneration.
Moreover, further validation experiments regarding the protein candidates from the
interactome should aim at identifying their role in the context of naturally aggregating
proteins: are they sequestered by protein aggregates? Can their overexpression
improve neuronal viability? If so, by which mechanism? Is the candidate relevant for
more than one disease? Is the candidate expression modified in postmortem material
of patients?
Finally, further mechanistic studies to answer the fundamental question of how
protein aggregation leads to cell death are still necessary. Although vast advances
have been made in the past decades to identify the multiple dysfunctional mechanisms
in NDs, this fundamental question still cannot be answered. In this regard, artificial
β-sheet proteins can be used as a tool to help unravel key mechanisms of aggregation-
driven cytotoxicity.
5.3 β23 protein aggregation effects in vivo in a new inducible
mouse model
Studies in cultured neurons are very valuable for mechanistic investigations.
However, processes in a living animal involve several cell types, interconnected
with each other in particular manners, and are therefore much more complex. To
study the effects of amyloid-like protein aggregation in the brain of a complex liv-
ing organism, we generated a novel β23 transgenic mouse model of protein aggregation.
5.3.1 Generation of a Tet-inducible β23 mouse model
We made use of a Tet-inducible system to enable temporal and spatial control of
β23 expression. A responder transgene was generated consisting of a third generation
Tet-responsive element (TRE) placed upstream of the β23-encoding cDNA. We were
concerned about how mCherry would influence aggregation in vivo, but were interested
in generating a model that would be used for functional in vivo imaging, which
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would require the fusion protein β23mCherry for protein identification. Therefore,
we kept both possibilities open by placing an frt-flanked IRES sequence in between
β23 and mCherry (Fig. 4.12). The widely used CamKIIα:tTa activator mouse line
was used to induce expression and restrict it to forebrain structures [205]. More-
over, the broader NEFH:tTa driver line [252] was used to induce expression in the
whole CNS. Of note, most of the following discussion will focus on the CamK;β23
analyses, since these mice have been extensively studied during this thesis. In ad-
dition, the final part of the discussion will address the recent results in NEFH;β23 mice.
Before discussing the results from the analyses of the novel β23 models, there
are several remarks that can be made regarding the strategy and implications of the
line. First, the choice of β23 to be expressed in a mouse was based on the published
toxicity data in Hek293T cells, which described this protein as the most aggregating
and toxic of the three artificial proteins analyzed [81]. In light of my data in primary
neurons, generating and studying a β4 mouse model could bring insight into the toxic
mechanisms of a less aggregating protein, which may resemble those of oligomeric
species.
Second, placing the cDNA expression construct under the control of the pTRE3G
promoter is a new strategy for Tet-inducible mouse models of neurodegeneration.
Some models have been generated using the bidirectional tet operator (BiTetO), such
as the HD94 model of HD [257], the TauRD models [258], and the mutant α-synuclein
model with restricted expression to dopaminergic neurons in the midbrain [182]; while
other models, an Aβ model [259], the tauP301L model Tg4510 [77] and two TDP-43
models [260, 252] made use of the prion promoter PrP. In comparison to biTetO,
pTRE3G is a further optimized promoter version with very low basal expression and
high maximal expression after induction [261], whereas there is no available data
comparing expression induction between pTRE3G and PrP.
Next, the recombined line (expressing fused β23mCherry) would allow for functional
two-photon in vivo imaging, enabling also the characterization of aggregation dynamics
over months. This imaging technique has not been applied in many neurodegeneration
studies yet, and our mouse model may be useful to study aggregation in different cell
populations and its effects on the circuitry in vivo. Moreover, mCherry fluorescence
would facilitate protein detection avoiding injection of amyloid dyes.
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Finally, to restrict β23 expression to excitatory neurons of the forebrain, we decided
to use the CamKIIα:tTa driver mouse line [205]. We selected this line because it was
previously used to generate and characterize several neurodegeneration mouse models
[257, 259, 77, 258, 260], which would enable us to compare our mouse to existing
models of naturally aggregating proteins.
However, it has been reported that tTa expression in the CamKIIα:tTa mouse line
can lead to dentate gyrus degeneration and influence behavior results depending on
the genetic background [251], demonstrating that the tTa is not just an inert control
element. This study showed that generation F1 with CBA x C57BL/6 and C3H/He
x C57BL/6, but not pure C57BL/6 background induced degeneration, whereas pure
C57BL/6 resulted in poor Morris water maze performance. Degeneration in the
dentate gyrus could be prevented by Dox treatment during development. Nonetheless,
reporting of Dox treatment, genetic background, and single transgenic controls usage
among different studies has been very variable and partly misleading. For example,
double transgenic animals were compared to non-transgenic controls, instead of to
single transgenic animals [260], or non-transgenic and single transgenic animals were
pooled in a control group [77]. Overall, the use of the activator CamKIIα:tTa line in
our project involved careful management of the mouse colony and reporting of control
genotypes.
5.3.2 Effects on brain macrostructure by β23 expression
As expected, we detected restricted β23 and mCherry expression in the forebrain
of CamK;β23 mice and only in positive double transgenic animals (Fig. 4.13).
Immunostaining against mCherry showed conspicuous expression in neurons of several
brain regions, such as the olfactory bulb, the whole cortex, including the motor,
somatosensory, and entorhinal cortex; the striatum, the hippocampus, and the amyg-
dala. These regions of expression coincide with previously published expression data
of the CamKIIα:tTa line [262]. However, in the hippocampus of our mice, expression
was restricted to CA1, although expression in CA1, CA2, CA3, and dentate gyrus was
expected. Given that our mouse line is a transgenic line, this limited expression might
be related to the transgene’s integration site.
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Moreover, we confirmed β23 expression via myc immunostaining. Noteworthy,
laborious troubleshooting was required for myc staining to work in vivo (see section
3.2.16). Nevertheless, we did not detect myc-positive neurons in the CA1 region of
the hippocampus and only a few in the striatum. This differential expression suggests
that in the CamK;β23 unrecombined line β23 and mCherry might not be expressed
at equimolar ratios and only the mCherry part of the construct is expressed in CA1.
This issue is however surprising, since it was reported that in constructs containing
IRES, the upstream to the IRES part of the construct is usually expressed higher than
the downstream part [263], and not the opposite.
Importantly, neither myc nor mCherry expression were detected in absence of
tTa transactivator in single transgenic β23+ mice, indicating the absence of leaki-
ness in expression (Fig. 4.13 B). This lack of leakiness supports our choice of the
pTRE3G promoter, given that tau expression has been identified in transactivator ab-
sence in the Tet-inducible P301L tau model [264], which is driven by the PrP promoter.
At whole-brain level, we measured a reduction in brain weight in double positive
CamK;β23 transgenic mice, along with a reduction in cortical width, while the
body weight remained constant (Fig. 4.15). Importantly, reduced brain weight and
progressive body weight loss are common phenotypes observed in mouse models
of neurodegenerative diseases [77, 182, 252, 202]. In our mice, the difference in
brain weight of double transgenic versus control mice became more pronounced with
increasing age. However, this difference was given by the augmentation in brain weight
in control mice, not because brains of double transgenic mice progressively lost weight,
as it is commonly observed for ND mouse models. In addition, already at the early
age of 4 weeks, we detected a slight reduction in the brain weight of double transgenic
CamK;β23 unrecombined mice. Altogether, these data suggest that the reduced
brain weight detected in double transgenic mice might be caused by an effect of β23
expression (maybe also due to combined tTa expression) during brain development,
rather than by a progressive neurodegenerative phenotype.
Finally, to prevent the possible neurodevelopmental effect, we administered Dox
to CamK;β23 unrecombined mice from conception until weaning and measured their
brain weight. Unfortunately, although the effects on development were circumvented,
we detected no brain weight loss in Dox-treated mice even in very aged mice (Fig.
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4.15 F). Nonetheless, we noticed in preliminary observations of mCherry fluorescence
that expression levels in Dox-treated mice were low and expression was detected
in fewer cells than in non-treated mice. In addition, expression levels stayed low
with age, which might have resulted in the lack of brain atrophy derived from β23
expression. Considering that other studies using the CamKIIα:tTa driver line reported
good expression-induction and development of neurodegenerative phenotypes after
Dox removal [257, 77], the low expression levels in our mice might be linked to the
integration site of the transgene. Hence integration mapping would be necessary to
investigate how β23 expression is regulated during and after development.
Differences between the unrecombined and recombined line in CamK;β23 mice
Besides working with unrecombined mice, we also studied mice of our recombined
line, in which the fused protein β23mCherry was expressed in double transgenic mice
upon breeding with CamKIIα:tTa mice. Notably, when observing the perfused brains
directly after withdrawal, we noticed that fluorescence in brains of recombined mice
was clearly brighter than fluorescence in unrecombined brains. This observation fitted
to accumulation of the fused protein, since β23mCherry aggregates in cultured neurons
also appeared brighter than the diffused protein or than mCherry alone.
As we had done for the CamK;β23 unrecombined line, we confirmed expression
in the forebrain of recombined mice by staining against mCherry. The expression
pattern of the recombined line looked very similar to that of the unrecombined line.
However, although in principle the unrecombined and recombined mice should present
expression in the same brain regions, recombined mice lacked hippocampal CA1
expression (Fig.4.16 C).
In addition, comparison of cortical expression between unrecombined and recom-
bined mice, showed strong β23mCherry expression in neural processes of recombined
mice, while mCherry was stronger in the soma in the unrecombined animals (Fig.4.16
D). Possibly, less neurons were labeled in the cortex of β23mCherry-expressing mice,
suggesting that myc staining might be more accurate to detect transgene expression in
unrecombined mice, especially given that β23 and mCherry might not be expressed at
equimolar levels. These observations should be taken into account for further studies
in NEFH;β23 mice.
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Furthermore, β23mCherry aggregates were readily detected in the recombined line
via mCherry staining, although β23mCherry did not seem to localize to the nuclear
membrane, as observed for β23 in unrecombined mice (Fig.4.17 E). Analysis of myc
staining in CamK;β23 unrecombined and recombined mice would be necessary for
precise comparison of expression between the two lines. Moreover, the number of
expressing neurons should also be quantified in further experiments.
Finally, we measured the brain weights of non-Dox treated CamK;β23 unrecom-
bined and recombined mice. As mentioned above, unrecombined β23-expressing
double transgenic mice presented reduced brain weight when compared to controls.
However, we did not detect a reduction in brain weight in recombined β23mCherry-
expressing mice at 40-42 weeks of age (Fig.4.16 F). These data indicated that β23 and
β23mCherry expression may lead to different effects, β23mCherry being less toxic in
vivo. It is possible then that mCherry fusion alters aggregate structure and reduces
its toxicity. To investigate this hypothesis, in-depth structural characterization of β23
and β23mCherry aggregates in neurons, for example by Cryo-electron tomography
[265], would be necessary. Moreover, amyloid stainings such as Thioflavin could be
useful to detect if β23mCherry may be less amyloidogenic than β23.
Overall, we have detected β23 in the forebrain of CamK;β23 unrecombined and
recombined mice. Moreover, we have confirmed the presence of protein aggregates in
both lines. However, β23 expression showed an effect in brain weight only in CamK;β23
unrecombined mice. Our data does not exclude that CamK;β23 recombined mice may
develop a degeneration phenotype at a later age, as indeed many neurodegeneration
models develop a phenotype at very advanced ages [181, 266]. Nonetheless, we decided
to focus our further experiments on CamK;β23 unrecombined mice.
5.3.3 β23 mice as a model to study nucleocytoplasmic transport
At cellular level, we detected β23 aggregates in the soma and neurites in CamK;β23
mice (Fig.4.17 C and 4.18 D). Remarkably, we noticed an enrichment of small β23
aggregates around the nucleus, probably at the nuclear membrane (Fig.4.17 A,B). This
particular aggregation localization opened up the possibility that β23 interferes with
NCT in vivo. In fact, a previous report showed impairment of NCT due to artificial
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β-sheet expression in vitro [204].
Nucleocytoplasmic transport impairment arose as a potential unifying toxicity
mechanism in NDs in recent years (see section 2.2.2). Therefore, we performed im-
munostainings to identify possible signs of NCT malfunction in neurons of CamK;β23
unrecombined mice. Indeed, we could identify RanGAP1 partial colocalization with
β23 aggregates, possibly interfering with RanGap1 correct function. However, this
colocalization was observed by confocal imaging and should be confirmed with a
microscopy technique that allows for better resolution, such as STED microscopy
[267]. Given that RanGAP1 is important to maintain the gradient of Ran-GTP in the
nucleus and Ran-GDP in the cytoplasm, providing directionality to nucleocytoplasmic
transport, alterations in RanGAP1 might lead to changes in the rate and direction of
active transport [128].
Moreover, we identified Nup153 mislocalization to β23 aggregates (Fig.4.19). This
nuclear pore protein is a member of the nuclear pore basket and is critical for nuclear
pore biogenesis [268]. Thus, its mislocalization may impair nuclear pore integrity.
To date, our observations regarding nucleocytoplasmic transport integrity in β23
mice have been qualitative and further experiments that quantify the degree of protein
mislocalization will be necessary. In addition, studying how the number of neurons
with β23 localization at the nuclear envelope varies with age, would also shed light
on the age-dependent mechanisms and dynamics of NCT impairment. Moreover, it
will be interesting to find out, if β23 expression can interfere with RNA export, or if
it interferes with both RNA and protein transport by clogging the nuclear pores, as
observed for DPRs in ALS/FTD [129, 133]. All these open questions can be addressed
as well using NEFH;β23 mice, in which we also detected β23 aggregates around the
nucleus in preliminary observations. In addition, our lentivirus harboring the same
construct as the mouse model will be a potent tool for mechanistic studies on NCT
function.
5.3.4 Lack of behavioral abnormalities in Camk;β23 unrecombined mice
In humans affected by NDs, the consequences of aggregate pathology and neurode-
generation are clinical symptoms affecting cognition and motor function. Therefore, we
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investigated if aggregation of artificial β23 protein could lead to effects in behavioral
function in our mouse model.
We performed a wide variety of memory and motor tests in big Camk;β23 unrecom-
bined mice cohorts including male and female mice. Importantly, and in contrast to
what was done in previously published studies, we included the two single transgenic
control groups in the studies and analyzed them as independent groups, instead of
pooling them together.
Overall, we did not detect any remarkable differences among the three genotypes,
neither in motor nor in memory tests (Figs.4.21, 4.22 and 4.23). Although we detected
some trends or significant effects suggesting impaired function in some memory tests
in tTa+β23+ mice, these effects were only significant in comparison to β23+ control
mice, but not to tTa+ control mice. Similarly, performance in fine movement tests,
such as the balance beam and beam ladder, was worse in tTa+ and tTa+β23+ mice
in comparison to β23+ mice, but there was no difference between the two groups.
Thus, these data indicate that tTa expression by itself might be affecting behavioral
outcome.
As mentioned above, it was reported that tTa expression in CamkIIα:tTa mice
has a neurodegenerative effect on dentate gyrus granule cell layer and this effect is
dependent on genetic background [251]. Aiming to overcome this effect, we adopted a
breeding strategy that resulted in 25% CBA / 75% C57BL/6 genetic background in
our F1. Nevertheless, as shown by the brain weight and behavior data, tTa expression
in this genetic background still had an effect. Therefore, tTa expression might have
masked subtle effects driven by β23 expression. Perhaps strengthening of β23 over tTa
driven effects may be achieved by studying β23 homozygous mice.
Finally, as mentioned in section 2.3 of the introduction, most mouse models of NDs
do not reproduce the whole spectrum of the disease phenotype. For example, mice in
which Aβ deposition is driven in absence of APP overexpression, including knock-in
models, show plaques and gliosis, but subtle behavioral abnormalities [172, 173].
Moreover, neurodegenerative diseases are characterized by their progression and overt
manifestation at an advanced age. In agreement, some mouse models show behavioral
deficits very late in life, such as some PD models, which present behavior phenotypes
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not earlier than at 16 months of age [167]. Thus, analysis of further aged mice may
shed light on the validity of Camk;β23 mice as a neurodegeneration model.
5.3.5 Embryonic lethality in NEFH;β23 unrecombined mice
To circumvent the effects driven by CamkIIα:tTa expression and to target a
broader neuronal population throughout the CNS, we decided to cross our β23 mice
to NEFH:tTa mice. The strategy of changing the driver has already been used in a
TDP-43 mouse model of ALS: a first report characterized the line under expression
control of CamkIIα:tTa [260], and a second report used the same TDP-43 mouse model
in combination with tTa expression driven by the NEFH promoter [252]. Indeed,
our NEFH;β23 mice might be most valuable to study protein aggregation toxicity
mechanisms with a focus on ALS.
In Camk;β23 unrecombined mice, β23 expression during development resulted
in brain atrophy, while the animal’s survival was not affected. On the other hand,
NEFH;β23 unrecombined were not viable, unless animals were raised on Dox to
prevent β23 expression during development. Why and how can the same pro-
tein lead to such different outcomes? As it has been pointed out throughout the
thesis, different expression levels induced by different promoters could likely have
an effect. Moreover, based on the NEFH promoter expression pattern, we would
expect β23 expression in motor neurons [252]. Perhaps proteostatic dysfunction and
malfunctioning NCT caused by β23 aggregation could be particularly detrimental
for vulnerable motor neurons in NEFH;β23 mice, as detected in ALS cellular and
animal models [269, 130]. Further experimental analysis will help unravel the mech-
anistics of β23 aggregation toxicity and its behavioral consequences in NEFH;β23 mice.
5.3.6 β23 in vivo: concluding remarks and outlook
We have generated a novel Tet-inducible β23 transgenic mouse model. Two variants
of β23 mice have been studied in this thesis: unrecombined and recombined mice.
Interestingly, while the two lines presented aggregate pathology in the forebrain of
Camk;β23 mice, only unrecombined mice presented reduced brain weight and cortical
thickness. Moreover, in unrecombined mice, small β23 inclusions accumulated in
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the nuclear envelope of neurons, suggesting an interference with nucleocytoplasmic
transport. Despite these observations, β23 expression did not lead to the development
of any behavioral impairment in Camk;β23 mice, at least at the measured ages.
Overall, taking into consideration both in vitro and in vivo data, there might be
a discrepancy with regard to the cytotoxicity induced by the different constructs in
the two systems. That is, we have shown that fused protein β23mCherry expression
is more toxic than β23 to cultured neurons, whereas β23 in vivo seems to be more
toxic than β23mCherry. However, further experiments would be needed to clarify
this issue. As mentioned above, we did not compare the expression levels of β23 and
β23mCherry in cultured neurons. This comparison, along with the neuronal viability
assessment, would be necessary to make any final conclusion on the cytotoxicity of the
constructs. Moreover, confirming that the two mouse lines express the same levels of
β-sheet protein would as well be needed.
At this point, taking into consideration our results in Camk;β23 and NEFH;β23
mice, our data suggest that the presence of an amyloid-like aggregated protein in the
CNS is enough to drive a neurodegeneration phenotype. However, vulnerability of
different neuronal subpopulations can strongly influence the phenotype severity. This
is reminiscent of the selective vulnerability of particular neuronal subpopulations in
the development of different NDs [110].
Importantly, further studies should address the age-dependency of the neurodegen-
eration in β23 mice. We need to make sure that mice develop a progressive phenotype
with age, not only a developmental phenotype. HD mice with HTT expression
restricted to development recapitulated characteristic features of HD [270], suggesting
that aberrant mechanisms during development are crucial to disease progression.
However, relevance of these findings for other NDs or human disease has not been
confirmed. Analysis of aged Dox-treated NEFH;β23 unrecombined mice will be crucial
to address this issue.
Moreover, our studies have been very much focused on neuronal effects. Recent
research has reinforced the role of glial cells as driving forces in neurodegeneration
[65] and investigating glial reactivity mechanisms in β23 mice would be necessary for
complete pathology characterization in this model. In addition, another option would
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be expressing β23 in glial cells and analyzing the effects on neuronal survival and at
circuit level to study the non-cell autonomous component of neurodegeneration.
Further research avenues using the β23 mice could focus on molecular mechanisms.
Especially, analyzing nucleocytoplasmic transport function might be particularly
relevant for the neurodegeneration field, given that it is still an open question whether
common NCT pathways are disrupted by different protein aggregates.
Finally, there are three more lines of investigation that we did not exploit yet,
which might help shed light on fundamental questions of protein aggregation toxicity.
One is the investigation of protein aggregation effects at circuit level. Functional in
vivo imaging of neurons bearing aggregates versus neurons without aggregates could
be done in the recombined line to study effects of aggregation on neuronal activity.
Moreover, β23mCherry expression could be stopped at different ages with Dox to
monitor the aggregate clearing capacity with aging in vivo, along with its effects
on neuronal activity. These experiments may be useful for assessment of the ideal
timepoint to administer therapeutics to reverse disease progression. Alternatively, the
third experimental line would focus on protein seeding and spreading. It has not been
tested yet, whether artificial amyloid-like protein aggregation can be seeded, whether
it can spread to other brain regions, or whether artificial proteins can seed naturally
aggregating proteins, such as tau or synuclein. If amyloid-like protein aggregation
could be seeded, it would indicate that amyloid structure is sufficient to induce
conformational changes in soluble proteins leading to aggregation. This would imply
the possibility of proteins cross-seeding each other, which may lead the field into the
development of structure-targeting therapeutics [7].
6
Conclusions
In this thesis, I provide the first characterization of the effects elicited by arti-
ficial amyloid-like aggregating proteins on cultured neurons and in a novel mouse
model. We show that β4mCherry and β23mCherry form aggregates in primary
neurons. Moreover, expression of β4mCherry and β23mCherry results in neuronal
morphology and progressive time-dependent neuronal death. Given that we detect
reduced phosphorylated Akt after BDNF treatment in β-sheet protein expressing neu-
rons, impaired neurotrophic signaling might be involved in the cause of neuronal death.
In addition, we identify the neuronal interactome of mCherry-tagged artificial
β-sheet proteins. Thereby, we show that aggregating proteins engage in aberrant inter-
actions with proteins involved in a variety of cellular functions. Some of these proteins
are necessary for neuronal survival, as revealed by a loss of function Crispr/Cas9
screen. The list of interactor proteins we provide constitutes a resource of candidates
potentially involved in common mechanisms of aggregation toxicity.
Finally, we generated a novel inducible transgenic mouse line to study amyloid-like
aggregation effects in vivo. β-sheet protein expression in the forebrain results in
aggregate formation, brain atrophy, and engagement of nucleocytoplasmic transport
components with the aggregates. However, we detect no behavioral deficits in these
animals. β-sheet protein expression in the whole CNS is on the other hand lethal.
These novel mouse lines may be useful tools to study effects on nucleocytoplasmic
transport which result from protein aggregation.
Overall, we identified neurodegeneration-relevant pathways, such as neurotrophic
signaling and nucleocytoplasmic transport, by utilizing artificial amyloid-like aggre-
gating proteins. Our results confirm the validity of these model proteins to investigate
gain of function mechanisms of protein aggregation. Further investigations combining
the use of artificial and naturally aggregating proteins may enhance the identification
of therapeutic targets for neurodegenerative diseases.
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Supplementary methods
This section contains the description of methods that were key to my thesis, but
performed by collaborators. Proteomic analyses were performed by Daniel Hornburg,
who kindly provided the protocols. Behavior tests were performed by the German
mouse clinic (Helmholtz Zentrum Muenchen) and the protocols were kindly provided
by the staff.
7.1 Proteomics: methods description
LC-MS/MS
We separated peptides on a Thermo Scientific EASY-nLC 1000 HPLC system
(Thermo Fisher). Columns (75 µm inner diameter, 40-cm length) were in-house packed
with 1.9 µm C18 particles (Dr. Maisch GmbH). Peptides were loaded in buffer A (0.5%
formic acid) and separated with a gradient from 7% to 60% buffer B (80% acetonitrile,
0.5% formic acid) within 3.5 h at 200 nl/min. The column temperature was set to 60◦C.
A quadrupole Orbitrap mass spectrometer (Q Exactive, Thermo Fisher Scientific) was
directly coupled to the liquid chromatograph via a nano-electrospray source. The Q
Exactive was operated in a data-dependent mode. The survey scan range was set to
300 to 1.650 m/z, with a resolution of 70.000 at m/z 200. Up to the 15 most abundant
isotope patterns with a charge of =2 were subjected to Higher-energy collisional disso-
ciation [271] with a normalized collision energy of 25, an isolation window of 2 Th, and
a resolution of 17.500 at m/z 200. To limit repeated sequencing, dynamic exclusion of
sequenced peptides was set to 30 s. Thresholds for ion injection time and ion target
value were set to 20 ms and 3x106 for the survey scans and to 60 ms and 106 for the
MS/MS scans. Data were acquired using Xcalibur software (Thermo Scientific).
Solid phase extraction (StageTips)
Stage tips were prepared with 3xC18 material for rapid desalting and step elution
of the peptide mixtures. The stage tips were rinsed with Methanol and Buffer A (0,5%
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acetic acid). Then, the samples were added to the staging tips and washed with buffer
A. Buffer B (80% ACN, 0.5% acetic acid) was used to elute the samples. To remove the
solvent from the samples a Speedvac was used. Finally, the samples were resuspended
in 10 µl buffer A* (0.5% Acetic acid, 0.1% T rifluoroacetic acid (TFA), 2% Acetonitrile
(ACN)).
Complete proteome analysis
In order to identify all the proteins present in the cortical neurons after lysis,
complete proteome analysis was performed. Lysis buffer (4% SDS, 10 mM DTT, 10
mM Hepes pH=8) was applied for 10 min. Then, proteins were subjected to 45 min of
alkylation with 55 mM iodoacetamide. Acetone precipitation was performed to remove
the detergent. Acetone (-20◦C) was added to 100 µg of proteins to a final concentration
of 80% v/v, and proteins were precipitated overnight at -20◦C. The supernatant was
removed after 15 min of centrifugation (4◦C, 16,000xg) followed by washing with
80% acetone (-20◦C). Residual acetone was evaporated at RT. The protein pellet
was dissolved in 50 µl of 6 M urea/2 M thiourea, 10 mM Hepes, pH=8.0. Lys C
(1 µg) digestion was carried out for 2 h at RT. Then, samples were incubated with
1 µg Trypsin for overnight digestion. Finally, peptides were desalted on C18 StageTips.
Data Analysis and Statistics of MS data
To process MS raw files, we employed MaxQuant software (v. 1.5.7.10)[272]. We
used Andromeda [273], which is integrated into MaxQuant, to search MS/MS spectra
against the UniProtKB FASTA database. For the standard immunoprecipitation
and pre-loaded serum, enzyme specificity was set to trypsin and Lysine C. For the
antigen pre-digestion, the specificity was set only to Lysine C. For all the experiments,
N-terminal cleavage to proline and up to two miscleavages were allowed. Peptides had
to have a minimum length of seven amino acids to be considered for identification.
Oxidation, acetylation and deamidation were set as variable modifications (maximum
number of modifications per peptide=5). A false discovery rate (FDR) cutoff of 1%
was applied at the peptide and protein levels. Initial precursor mass deviation of up to
4.5 ppm and fragment mass deviation up to 20 ppm were allowed. Precursor ion mass
accuracy was improved by time-dependent recalibration algorithms in MaxQuant.
The cutoff score (delta score) for accepting individual MS/MS spectra was 17. As
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a library for matches we used the proteome fasta file from Mus musculus (Taxon
identifier: 10090). Nonlinear retention time alignment [274] of all measured samples
was performed in MaxQuant. “Match between runs,” which allows the transfer of
peptide identifications in the absence of sequencing, was enabled with a maximum
retention time window of 0.7 min. Furthermore, we filtered our data by requiring a
minimum peptide ratio count of 1 in MaxLFQ [275]. Protein identification required at
least one razor peptide [272]. Proteins that could not be discriminated on the basis of
unique peptides were grouped into protein groups. For statistical and bioinformatic
analysis, as well as for visualization, we used the open PERSEUS environment, which
is part of MaxQuant. To gain better behavior of the data in statistical tests, we trans-
formed the numerical data to log2(x). Moreover, proteins were filtered for common
contaminants and proteins identified only by site modification and reverse proteins
were excluded from further analysis. To figure out, if any of the samples is an out
layer, we displayed a hierarchical clustering map. To identify the most discriminating
proteins in group wise comparisons, first we performed imputation of missing values
with a normal distribution (width = 0.3; shift = 1.8) as described elsewhere [274].
For pairwise comparison of proteomes and determination of significant differences
in protein abundances, t-test statistics were applied with a permutation-based FDR
of 5% and S0 of 1. The resulting significant outliers for each of the sample pairs
were analyzed for gene ontology cellular component (GOCC)[216], biological process
(GOBP), Molecular function (GOMF), protein complexes (Corum)[276] and protein
families and domains (Pfam) [277] annotation enrichment. For visual representation,
we displayed the data in a scatter plot.
To calculate the content of disordered regions, we employed R (rjson and seqinr
libraries). First, we mapped amino acids that are predicted with low complexity long
region (IUPred-L) to sequences of proteins that are significant outliers in either of
the β-sheet interactomes as well as for the entire population of proteins identified in
the interactomes. Proteins were only considered if they were detected with at least
three valid values in at least one condition. Next the ratio of all amino acids and
those predicted with low complexity was calculated. To determine the significance
of differences between the individual populations, a two-sample Wilcoxon tests was
performed on the ratio distributions.
Finally, to depict common and exclusively interaction proteins we employed R
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basic and igraph functions. Significantly enriched proteins were plotted with the edge
width scaled by enrichment score.
7.2 Mouse behavior analysis
Male and female mice of the three following genotypes were analyzed: β23+, tTa+,
tTa+ β23+. Fifteen animals per sex and genotype were analyzed in all tests, except
for tTa+ males, which were only fourteen. Therefore, a total of 89 mice were studied.
Mice were acclimatized to the lab environment at least 15 minutes, before the start of
each habituation or test session. Table 7.1 summarizes all performed tests and the age
at which they were performed.
Behavior test Age in weeks
Open field 22
Y-maze test 23
Grip strength 31
Rotarod 31
Balance beam 33
Horizontal ladder 33
Social discrimination 34
Object recognition 36
Place and reversal learning in Intellicage 43
Table 7.1: List of behavior tests.
7.2.1 Open field
The Open Field test was carried out according to the standardized phenotyping
screens utilized by the International Mouse Phenotyping Consortium (IMPC) and
available at https://www.mousephenotype.org/impress/protocol/81/7. The light
apparatus and software ActiMot2 were purchased from TSE-system. The light
apparatus consisted of a square-shaped frame with two pairs of light-beam strips, each
pair consisting of one transmitter strip and one receiver strip. These basic light barrier
strips were arranged at right angles to each other in the same plane to determine the
7.2 Mouse behavior analysis 145
X and Y coordinates of the animal, and thus its location (XY frame). Each strip was
equipped with 16 infrared sensors with a distance of 28mm between adjacent sensors.
With two further pairs of uni-dimensional light-barrier strips (Z1 and Z2), rearing
could be detected in addition to location.
The test apparatus where the mouse was placed consisted of a transparent and
infrared light permeable acrylic test arena (internal measurements: 45.5 x 45.5 x 39.5
cm) with a smooth floor. The illumination levels were set at approximately 150 lux
in the corners and 200 lux in the middle of the test arena. At the beginning of the
experiment, all animals were transported to the test room and left undisturbed for at
least 30 minutes before the testing started. Then each animal was placed individually
into the middle of one side of the arena facing the wall and allowed to freely explore
the arena for 20 min.
7.2.2 Y-maze
Spontaneous alternations were assessed using the Y-Maze, which was made of
opaque light grey PVC and had 3 identical arms (30 x 5 x 15 cm) placed at 120◦
from each other; illumination in the center of the maze was 100 lux. Each mouse
was placed at the end of one arm and allowed to move freely through the maze
during a 5-minute session. Spontaneous alternations (defined as consecutive entries
into all three arms without repetitions in overlapping triplet sets) were scored. Total
numbers of arm entries were collected cumulatively over the 5 minutes. Spontaneous
alternation performance percentage is defined as the ratio of actual (total alternations)
to possible alternations (total number of triplets) x 100. Measured parameters included
spontaneous alternations, alternate arm returns and same arm returns.
7.2.3 Grip strength
The grip strength meter system was purchased from Bioseb. Mice were allowed to
catch the grid with either 2 or 4 paws. Three trials, all measured within one minute,
were undertaken for each mouse.
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7.2.4 Rotarod
Mice were placed on the Rotarod (Bioseb) at an accelerating speed from 4 to 40
rpm for 300 sec with 15 min between each trial. They were given three trials at the
accelerating speed on one day. The mean latency to fall off the Rotarod during the
trials was recorded.
7.2.5 Beam walk
In the beam walk test, mice had to traverse a distance of 90 cm on series of
elevated, narrow beams (diameters beams 1-4: square 20 mm, round 22 mm, square
12 mm, round 15 mm) to reach their respective home cage. Mice were trained before
with the largest beam by habituating them to the apparatus and letting them cross
the beam from each near, mid and far distance once. The quantified parameters in the
test were: traversing time, number of stops, and fore- and hind-paw slips; which were
recorded manually. The means of 3 trials per mouse were used for data analysis.
7.2.6 Beam ladder
The beam ladder test was performed shortly after the beam walk, without previous
habituation. In this test, mice were required to traverse a narrow horizontal ladder
equipped with metal beams of 1 mm in diameter to reach their respective home cage.
The beams were placed in various and irregular distances to each other. Traversing
time as well as fore- and hind-paw slips were recorded manually, and the means of 3
trials per mouse were used for data analysis.
7.2.7 Social discrimination
The Social Discrimination procedure consisted of two 4 min exposures of stimulus
animals (ovariectomized 129Sv females) to the test animal in a fresh cage to which
the test animal had been moved 2 h prior to testing. All stimulus animals are
identified using coloured non-toxic non-permanent paint markers on the tail. After
a retention interval of 2 h, the stimulus animal was presented to the test animal
together with an additional, previously not presented stimulus animal. A separate
“familiar” and “unfamiliar” stimulus animal was assigned to each test animal. The
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duration of investigatory behavior of the test animal towards the stimulus animals
(familiar and unfamiliar) during this test phase was again recorded by a trained
observer with a hand-held computer. A social recognition index was calculated as time
spent investigating the unfamiliar stimulus mouse / time spent investigating both the
familiar and unfamiliar stimulus mouse.
7.2.8 Novel object recognition
Test mice were transferred to the behavior room 15 min prior to habituation or
testing. Habituation was done on two consecutive days before testing and mice were
placed in the empty arena and allowed to freely explore it for 10 minutes. On the
testing day, two identical objects were placed into the arena and the test mouse was
allowed to explore them for 5 minutes. This sample phase was performed a total of
three times. After retention intervals of 3 hours and 24 hours one of the previous
encountered familiar objects was substituted by a new, unfamiliar one. The mouse was
put back into the arena for another 5 minutes and exploration time was recorded. Mice
were recorded with the Ethovision video-tracking system and the analysis performed
with the Observer software (Noldus).
7.2.9 Place and reversal learning in Intellicage
Place and reversal learning were tested using the IntelliCage (NewBehavior, TSE
Systems). Mice were first injected with a transponder “White Label” (Planet ID)
under isoflurane anesthesia and given a recovery period of one week. Up to 10 mice
were then introduced into each Intellicage. Mice were housed according to genotype.
During the habituation phase (days 1-4), all doors protecting the water bottles
were open and mice had access to all corners to obtain water. On days 4-7, a nosepoke
adaptation period trained the mice to nosepoke for water. All doors closed during this
time and the mice had to nosepoke to open the door to get water. The door opened
only with the first nosepoke and closed 4 seconds later. They could access water in
all four corners. On days 7-14, controlled by the Intellicage software, each mouse
could only obtain water in one of the Intellicage corners (designated the “correct
corner”). This was, for each mouse, the least preferred corner during the nosepoke
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adaptation phase. Any attempts to access water in the other three corners were
recorded as an error (“incorrect nosepoke”). The percentage error rate (Number
incorrect nosepokes/total number nosepokes x 100) was calculated.
For the reversal learning paradigm, on days 14-21, the assigned corner in which
each mouse could access water switched to the opposite corner. The percentage error
rate (as calculated for place learning) was determined for each animal.
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A. Al-Chalabi, T. Hortobágyi, and C. E. Shaw, “p62 positive, TDP-43 nega-
tive, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hip-
pocampus define the pathology of C9orf72-linked FTLD and MND/ALS,” Acta
neuropathologica, vol. 122, no. 6, pp. 691–702, 2011.
REFERENCES 165
[50] P. E. Ash, K. F. Bieniek, T. F. Gendron, T. Caulfield, W.-L. Lin, M. DeJesus-
Hernandez, M. M. Van Blitterswijk, K. Jansen-West, J. W. Paul III, R. Rade-
makers, et al., “Unconventional translation of C9ORF72 GGGGCC expansion
generates insoluble polypeptides specific to c9FTD/ALS,” Neuron, vol. 77, no. 4,
pp. 639–646, 2013.
[51] K. Mori, S.-M. Weng, T. Arzberger, S. May, K. Rentzsch, E. Kremmer, B. Schmid,
H. A. Kretzschmar, M. Cruts, C. Van Broeckhoven, et al., “The C9orf72
GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in
FTLD/ALS,” Science, vol. 339, no. 6125, pp. 1335–1338, 2013.
[52] T. Zu, B. Gibbens, N. S. Doty, M. Gomes-Pereira, A. Huguet, M. D. Stone,
J. Margolis, M. Peterson, T. W. Markowski, M. A. Ingram, et al., “Non-ATG-
initiated translation directed by microsatellite expansions,” Proceedings of the
National Academy of Sciences, vol. 108, no. 1, pp. 260–265, 2011.
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